Supplement to: Prevalence, imaging patterns, and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis

Greta M. Joy, Omri A. Arbiv, Carmen K. Wong, Stacey D. Lok, Nicola A. Adderley, Krzysztof M. Dobosz, Kerri A. Johannson, Christopher J. Ryerson

TABLE OF CONTENTS

SUPPLEMENTAL FIGURES

Figure S1a Prevalence of RA-ILD, study level data



Abbreviations: ILD: interstitial lung disease, RA: rheumatoid arthritis

Figure S1b Prevalence of SSc-ILD, study level data



Abbreviations: ILD: interstitial lung disease, SSc: systemic sclerosis

Figure S1c Prevalence of IIM-ILD, study level data



Abbreviations: IIM: idiopathic inflammatory myositis, ILD: interstitial lung disease

Figure S1d Prevalence of pSS-ILD, study level data



Abbreviations: ILD: interstitial lung disease, pSS: primary Sjögren syndrome

Figure S1e Prevalence of MCTD-ILD, study level data



Abbreviations: ILD: interstitial lung disease, MCTD: mixed connective tissue disease

Figure S1f Prevalence of SLE-ILD, study level data



Abbreviations: ILD: interstitial lung disease, SLE: systemic lupus erythematosus

Figure S2a Study level data on RA-ILD CT patterns



Abbreviations: CT: computed tomography, ILD: interstitial lung disease, NSIP: non-specific interstitial pneumonia, OP: organizing pneumonia, other: other and undifferentiated, RA: rheumatoid arthritis, UIP: usual interstitial pneumonia.

Figure S2b Study level data on SSc-ILD CT patterns



Abbreviations: CT: computed tomography, ILD: interstitial lung disease, NSIP: non-specific interstitial pneumonia, other: other and undifferentiated, SSc: systemic sclerosis, UIP: usual interstitial pneumonia.

Figure S2c Study level data on IIM-ILD CT patterns



Abbreviations: CT: computed tomography, IIM: idiopathic inflammatory myositis, ILD: interstitial lung disease, NSIP: non-specific interstitial pneumonia, OP: organizing pneumonia, other: other and undifferentiated, UIP: usual interstitial pneumonia.

Figure S2d Study level data on pSS-ILD CT patterns



Abbreviations: CT: computed tomography, ILD: interstitial lung disease, LIP: lymphocytic interstitial pneumonia, NSIP: non-specific interstitial pneumonia, OP: organizing pneumonia, other: other and undifferentiated, pSS: primary Sjögren syndrome, UIP: usual interstitial pneumonia.

Figure S2e Study level data on MCTD-ILD CT patterns



Abbreviations: CT: computed tomography, ILD: interstitial lung disease, MCTD: mixed connective tissue disease, NSIP: non-specific interstitial pneumonia, other: other and undifferentiated, UIP: usual interstitial pneumonia.

Figure S2f Study level data on SLE-ILD CT patterns



Abbreviations: CT: computed tomography, ILD: interstitial lung disease, NSIP: non-specific interstitial pneumonia, OP: organizing pneumonia, other: other and undifferentiated, SLE: systemic lupus erythematosus, UIP: usual interstitial pneumonia.

Figure S2f Study level data on UCTD-ILD CT patterns



Abbreviations: CT: computed tomography, ILD: interstitial lung disease, NSIP: non-specific interstitial pneumonia, other: other and undifferentiated, UCTD: undifferentiated connective tissue disease, UIP: usual interstitial pneumonia.

SUPPLEMENTAL TABLES

Table S1a Embase search strategy

1	Exp rheumatoid arthritis/
2	Rheumatoid.mp.
3	Exp scleroderma/
4	Scleroderma.mp.
5	“systemic sclero*”.mp.
6	Exp Sjoegren syndrome/
7	Sj#gren*.mp.
8	Myositis/
9	Antisynthetase syndrome/
10	Dermatomyosistis/
11	Polymyositis/
12	Dermatomyositis.mp.
13	Polymyositis.mp.
14	“antisynthetase syndrome”.mp.
15	“inflammatory myositis”.mp.
16	Connective tissue disease/
17	“connective tissue dis*”.mp.
18	“collagen vascular dis*”.mp.
19	Exp mixed connective tissue disease/
20	“mixed ctd”.mp.
21	“undifferentiated ctd”.mp.
22	Exp systemic lupus erythematosus/
23	Lupus.mp.
24	or/1-23
25	Exp interstitial lung disease/
26	Exp lung fibrosis/
27	(interstitial$ adj3 (lung$ or pulmonary$ or pneomon$)).mp.
28	((pulmonary$ or lung$) adj3 (fibros$ or fibrot$)).mp.
29	ILD.mp.
30	UIP.mp.
31	NSIP.mp.
32	PPFE.mp.
33	“pleuroparenchymal fibroelastosis”.mp.
34	Bronchiolitis.mp.
35	Alveolitis.mp.
36	“organi#ing pneumon*”.mp.
37	or/25-36
38	Computer assisted tomography/ or computed tomographic angiography/ or high resolution computer tomography/ or multidetector computed tomography/ or spiral computer assisted tomography/ or x-ray computed tomography/
39	Hrct.mp.
40	“computed tomography”.mp.
41	“ct-scan”.mp.
42	Prevalence/
43	Prevalence.mp.
44	Risk factor/
45	“risk factor*”.mp.
46	Biomarker*.mp
47	or/38-46
48	24 and 37 and 47
49	Limit 48 to yr=”2000 – Current”

Table S1b Medline search strategy

1	exp Arthritis, Rheumatoid/
2	rheumatoid.mp.
3	exp Scleroderma, Systemic/ or exp Scleroderma, Localized/
4	scleroderma.mp.
5	"systemic sclero*".mp.
6	exp Sjogren's Syndrome/
7	sj#gren*.mp.
8	exp Dermatomyositis/
9	dermatomyositis.mp.
10	exp Polymyositis/
11	polymyositis.mp.
12	"antisynthetase syndrome".mp.
13	"inflammatory myositis".mp.
14	Connective Tissue Diseases/
15	"connective tissue dis*".mp.
16	"collagen vascular dis*".mp.
17	exp Mixed Connective Tissue Disease/
18	"mixed ctd".mp.
19	exp Undifferentiated Connective Tissue Diseases/
20	"undifferentiated ctd".mp.
21	exp Lupus Erythematosus, Systemic/
22	lupus.mp.
23	or/1-22
24	exp Lung Diseases, Interstitial/
25	exp Pulmonary Fibrosis/
26	(interstitial$ adj3 (lung$ or pulmonary$ or pneumon$)).mp.
27	((pulmonary$ or lung$) adj3 (fibros$ or fibrot$)).mp.
28	ild.mp.
29	Uip.mp.
30	Nsip.mp.
31	Ppfe.mp.
32	"pleuroparenchymal fibroelastosis".mp.
33	bronchiolitis.mp.
34	alveolitis.mp.
35	"organi$ing pneumon*".mp.
36	or/24-35
37	tomography, x-ray computed/ or computed tomography angiography/ or exp tomography, spiral computed/
38	HRCT.mp.
39	"computed tomography".mp.
40	"CT-scan".mp.
41	Prevalence/
42	Prevalence.mp.
43	protective factors/ or risk factors/
44	"risk factor*".mp.
45	biomarker*.mp.
46	or/37-45
47	23 and 36 and 46
48	limit 47 to yr="2020 -Current"

Table S2 Number of studies and total sample size addressing each objective. Data are reported as number of studies (included conference abstracts), N = total number of patients.

Connective Tissue Disease	Prevalence	Risk Factors for ILD	ILD Pattern	Risk Factors for ILD Pattern
Rheumatoid Arthritis	23 (6) N = 18,884	41 (10) N = 11,806	54 (13) N = 4,897	8 (1) N = 1,543
Systemic Sclerosis	69 (13) N = 31,096	33 (3) N = 24,281	22 (4) N = 1,263	
Idiopathic Inflammatory Myositis	27 (1) N = 3,781	22 (2) N = 3,349	23 (2) N = 1,305	1 (0) N = 48
Primary Sjögren Syndrome	11 (4) N = 3,899	8 (3) N = 3,716	16 (5) N = 722	1 (0) N = 170
Mixed Connective Tissue Disease	4 (1) N = 599	3 (2) N = 537	3 (0) N = 52	
Systemic Lupus Erythematosus	5 (2) N = 6,749	1 (1) N = 289	3 (0) N = 93	
Undifferentiated Connective Tissue Disease			3 (1) N = 91	1 (0) N = 66

Abbreviations: CT: computed tomography, ILD: interstitial lung disease

Table S3a Characteristics of studies addressing prevalence of RA-ILD, distribution of CT patterns of RA-ILD, and risk factors for development of RA-ILD.

Study Characteristic	Prevalence Studies	Risk Factor ILD Studies	CT Pattern Studies	Risk Factor CT Pattern Studies
Total Studies *Conference Abstracts*	23 *6*	41 *10*	54 *13*	8 *1*
Total N	18,884	11,806	-	1,543
N ILD	1,055	3,548	4,897	1,206
Demographics				
Age (years, mean)	54.3 (N = 2,845)	57.1 (N = 3,309)	61.3 (N = 1,667)	61.7 (N = 610)
Disease Duration (years, mean)	7.3 (N = 2,372)	7.7 (N = 2,530)	9.6 (N = 455)	10.2 (N = 88)
Sex (male)	841/4,153 (20.3%)	1,788/6,901 (25.9%)	1,577/3,960 (39.8%)	353/848 (41.6%)
Smoking History (ever)	677/3,097 (21.9%)	1,935/6,012 (32.2%)	1,695/3,604 (47.0%)	115/269 (42.6%)
Serology				
RF	1,742/2,608 (66.8%)	2,992/4,146 (72.2%)	2,786/3,294 (84.6%)	-
Anti-CCP	1,608/2,158 (74.5%)	2,579/3,570 (72.2%)	2,427/2,862 (84.8%)	-
Lung Function				
FVC (mean % predicted)	-	-	80.1 (N = 2,359)	-
TLC (mean % predicted)	-	-	76.9 (N = 783)	-
DLCO (mean % predicted)	-	-	60.2 (N = 2,117)	-

Abbreviations: ANA: antinuclear antibody, anti-CCP: anti-cyclic citrullinated peptide, CT: computed tomography, DLCO: diffusion capacity for carbon monoxide, FVC: forced vital capacity, ILD: interstitial lung disease, RA: rheumatoid arthritis, RF: rheumatoid factor, TLC: total lung capacity.

Table S3b Characteristics of studies addressing prevalence of SSc-ILD, distribution of CT patterns of SSc-ILD, and risk factors for development of SSc-ILD. No studies address risk factors for specific CT patterns.

Study Characteristic	Prevalence Studies	Risk Factor ILD Studies	CT Pattern Studies
Total Studies	69	33	22
Conference Abstracts	*13*	*3*	*4*
Total N	31,096	24,281	-
Total N ILD	11,330	7,499	1,263
Demographics			
Age (years, mean)	55.4 (N = 26,273)	55.3 (N = 22,625)	56.0 (N = 659)
Disease Duration (years, mean)	9.1 (N = 23,874)	8.8 (N = 21,314)	-
Sex (male)	4,747/31,250 (15.2%)	3,519/24,041 (14.6%)	127/837 (15.2%)
Smoking History (ever)	950/2,705 (35.1%)	482/1,549 (31.1%)	178/570 (31.2%)
CTD Subtype			
Limited SSc	17,541/30,139 (58.2%)	13,034/23,298 (55.9%)	194/378 (51.3%)
Diffuse SSc	9,503/30,734 (30.9%)	7,340/23,696 (31.0%)	183/378 (48.4%)
Serology			
ANA	21,837/22,892 (95.4%)	20,536/21,498 (95.5%)	319/345 (92.0%)
Anti-Scl70	8,280/28,103 (29.5%)	7,007/22,876 (30.6%)	260/486 (53.5%)
Anti-Centromere	10,562/28,237 (37.4%)	8,713/23,207 (37.5%)	69/476 (14.4%)
Anti-RNP	1668/21,598 (7.7%)	1,536/20,839 (7.4%)	-
Lung Function			
FVC	90.2 (N = 1,720)	93.3 (N = 1,257)	80.8 (N = 595)
DLCO (mean % predicted)	66.0 (N = 1,598)	63.7 (N = 1,257)	57.2 (N = 595)

Abbreviations: ANA: antinuclear antibody, CT: computed tomography, CTD: connective tissue disease, DLCO: diffusion capacity for carbon monoxide, FVC: forced vital capacity, ILD: interstitial lung disease, SSc: systemic sclerosis.

Table S3c Characteristics of studies addressing prevalence of IIM-ILD, distribution of CT patterns of IIM-ILD, and risk factors for development of IIM-ILD.

Study Characteristic	Prevalence Studies	Risk Factor ILD Studies	CT Pattern Studies	Risk Factor CT Pattern Studies
Total Studies	27	22	23	1
Conference Abstracts	*1*	*2*	*2*	*0*
Total N	3,781	3,349	-	-
Total N ILD	1,335	948	1,305	48
Demographics				
Age (years, mean)	49.5 (N = 722)	49.4 (N = 682)	52.1 (N = 602)	-
Sex (male)	912/2,980 (30.6%)	933/3,011 (31.0%)	366/1,110 (33.0%)	17/48 (35.4%)
Smoking History (ever)	-	-	137/392 (34.9%)	19/48 (39.6%)
CTD Subtype				
Dermatomyositis	1,997/3,447 (57.9%)	1,674/3,075 (54.4%)	414/866 (47.8%)	18/48 (37.5%)
Polymyositis	1,206/2,729 (44.2%)	871/1,892 (46.0%)	323/831 (38.9%)	6/48 (12.5%)
Serology				
ANA	280/589 (47.5%)	-	2	-
Anti-Jo-1	105/841 (12.5%)	63/599 (10.4%)	2	6/48 (12.5%)
Lung Function				
FVC	-	-	72.2 (N = 586)	-
DLCO (mean % predicted)	-	-	60.4 (N = 522)	-

Abbreviations: ANA: antinuclear antibody, CT: computed tomography, CTD: connective tissue disease, DLCO: diffusion capacity for carbon monoxide, FVC: forced vital capacity, IIM: idiopathic inflammatory myositis, ILD: interstitial lung disease.

Table S3d Characteristics of studies addressing prevalence of pSS-ILD, distribution of CT patterns of pSS-ILD, and risk factors for development of pSS-ILD.

Study Characteristic	Prevalence Studies	Risk Factor ILD Studies	CT Pattern Studies	Risk Factor CT Pattern Studies
Total Studies *Conference Abstracts*	11 *4*	8 *3*	16 *5*	1 *0*
Total N	3,899	3,715	-	170
Total N ILD	562	641	722	85
Demographics				
Age (years, mean)	50.4 (N = 1,460)	-	58.8 (N = 457)	-
Disease Duration (years, mean)	8.7 (N = 482)	-	-	-
Sex (male)	202/3,555 (5.7%)	201/3,447 (5.8%)	90/522 (17.2%)	16/170 (9.4%)
Smoking History (ever)	-	-	59/309 (19.1%)	-
Serology				
ANA	1,080/1,677 (64.4%)	1,473/1,683 (87.5%)	378/475 (79.5%)	163/170 (95.9%)
Anti-SSA/Ro	1,004/1,821 (55.1%)	1,507/1,851 (81.4%)	317/478 (66.3%)	141/170 (82.9%)
Anti-SSB/La	510/1,821 (28.2%)	791/1,832 (43.2%)	144/475 (30.4%)	78/170 (45.9%)
Lung Function				
FVC (mean % predicted)	-	-	66.53 (N = 350)	-
DLCO (mean % predicted)	-	-	58.6 (N = 350)	-

Abbreviations: ANA: antinuclear antibody, CT: computed tomography, CTD: connective tissue disease, DLCO: diffusion capacity for carbon monoxide, FVC: forced vital capacity, ILD: interstitial lung disease, pSS: primary Sjögren syndrome.

Table S3e Characteristics of studies addressing prevalence of SLE-ILD, distribution of CT patterns of SLE-ILD, and risk factors for development of SLE-ILD. No studies addressed CT pattern risk factors.

Study Characteristic	Prevalence Studies	Risk Factor ILD Studies	CT Pattern Studies
Total Studies *Conference Abstracts*	5 *2*	1 *1*	3 *0*
Total N	6,749	289	-
Total N ILD	498	23	93
Demographics			
Age (years, mean)	46.4 (N = 3,685)	-	55.4 (N = 10)
Disease Duration (years, mean)	9.1 (N = 3,685)	-	-
Sex (male)	360/3,974 (9.1%)	42/289 (14.5%)	15/65 (23.1%)
Smoking History (ever)	1,351/3,215 (42.0%)	-	16/55 (29.1%)
Serology			
ANA	-	-	-
Lung Function			
FVC (median % predicted)	-	-	81.8 (N = 55)
DLCO (median % predicted)	-	-	57.4 (N = 55)

Abbreviations: ANA: antinuclear antibody, CT: computed tomography, CTD: connective tissue disease, DLCO: diffusion capacity for carbon monoxide, FVC: forced vital capacity, ILD: interstitial lung disease, SLE: systemic lupus erythematosus.

Table S3f Characteristics of studies addressing prevalence of MCTD-ILD, distribution of CT patterns of MCTD-ILD, and risk factors for development of MCTD-ILD. No studies addressed risk factors for specific CT patterns.

Study Characteristic	Prevalence Studies	Risk Factor ILD Studies	CT Pattern Studies
Total Studies	4	3	3
Conference Abstracts	*1*	*2*	*0*
Total N	599	537	-
Total N ILD	327	292	52
Demographics			
Age (years, mean)	47.5 (N = 194)	49.1 (N = 144)	49.8 (N = 52)
Disease Duration (years, mean)	12.0 (N = 194)	13.4 (N = 144)	-
Sex (male)	15/234 (6.4%)	11/144 (7.6%)	6/52 (11.5%)
Smoking History (ever)	8/50 (16.0%)	-	13/ 37 (35.1%)
Serology			
RF	43/144 (30.0%)	43/144 (30.0%)	-
Anti-CCP	-	-	-
ANA	144/144 (100.5%)	144/144 (100.0%)	-
Lung Function			
FVC (mean % predicted)	82.0 (N = 50)	-	77.6 (N = 37)
TLC (mean % predicted)	87.0 (N = 50)	-	-
DLCO (mean % predicted)	87.0 (N = 50)	-	58.3 (N = 37)

Abbreviations: ANA: antinuclear antibody, anti-CCP: anti-cyclic citrullinated peptide, CT: computed tomography, DLCO: diffusion capacity for carbon monoxide, FVC: forced vital capacity, ILD: interstitial lung disease, MCTD: mixed connective tissue disease, RF: rheumatoid factor, TLC: total lung capacity.

Table S3g Characteristics of studies addressing prevalence of UCTD-ILD, distribution of CT patterns of UCTD-ILD, and risk factors for development of UCTD-ILD. No studies addressed prevalence of ILD or risk factors for ILD in UCTD.

Study Characteristic	CT Pattern Studies	Risk Factor CT Pattern Studies
Total Studies	3	1
Conference Abstracts	*1*	*0*
Total N	-	66
Total N ILD	91	41
Demographics		
Age (years, mean)	62.4 (N = 24)	57.7 (N = 66)
Sex (male)	21/50 (42.0%)	21/66 (31.8%)
Smoking History (ever)	13/24 (54.2%)	29/66 (44.0%)
Serology		
RF	8/50 (15.2%)	29/62 (46.8%)
ANA	34/50 (67.3%)	57/65 (87.7%)
Lung Function		
FVC (mean % predicted)	79.0 (N = 24)	-
DLCO (mean % predicted)	59.7 (N = 24)	-

Abbreviations: ANA: antinuclear antibody, CT: computed tomography, DLCO: diffusion capacity for carbon monoxide, FVC: forced vital capacity, ILD: interstitial lung disease, RF: rheumatoid factor, UCTD: undifferentiated connective tissue disease.

Table S4 List of references, study characteristics, and quality of evidence.

Reference	Year	Country	Connective Tissue Disease *1 = Rheumatoid arthritis* *2 = Systemic sclerosis* *3 = Idiopathic inflammatory myositis* *4 = Primary Sjögren syndrome* *5 = Mixed connective tissue disease* *6 = Systemic lupus erythematosus* *7 = Undifferentiated connective tissue disease*	Total N	ILD N	Newcastle Ottawa Scale *0-3 = Low* *4-6 = Medium* *7-9 = High*
Aguilera Cros C, Ruiz Roman A, Lisbona Munoz M, Luque Leon M, Leon Rubio P, Sanchez Serrano JP, Povedano Gomez J, Rodrigez Portal JA. Prevalence and significance of rheumatoid factor and anti-CCP in patients with interstitial lung disease and rheumatoid arthritis. In; 2016 2016: Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR 2016. United Kingdom. 75 (Supplement 2) (pp 956); BMJ Publishing Group; 2016.	2016	Spain	1	45	45	7
Alamoudi OSB, Attar SM. Pleuropulmonary manifestation in patients with rheumatoid arthritis in Saudi Arabia. *Annals of Thoracic Medicine* 2017: 12(4): 266-271.	2017	Saudi Arabia	1	419	30	8
Alberti ML, Paulin F, Toledo HM, Fernandez ME, Caro FM, Rojas-Serrano J, Mejia ME. Undifferentiated connective tissue disease and interstitial lung disease: Trying to define patterns. *Reumatologia Clinica* 2018: 14(2): 75-80.	2018	Mexico, Argentina	7	66	41	7
Alemao E, Doyle T, Sparks J, Rao A, Saini Y, Iannaccone C, Weinblatt ME, Shadick N. Evaluation of rheumatoid arthritis treatments and joint outcomes in rheumatoid arthritis-associated interstitial lung disease. In; 2019 2019: Annual European Congress of Rheumatology, EULAR 2019. Spain. 78 (Supplement 2) (pp 1099-1100); BMJ Publishing Group; 2019.	2019	USA	1	75	46	8

Alhamad E, Cal J, Alrajhi N, Paramasivam M, Alharbi W, Alessa M, Omair M, Alrikabi A, Alboukai A. Clinical characteristics and outcomes in patients with primary Sjogren's syndrome-associated interstitial lung disease. *Annals of Thoracic Medicine* 2021: 16(2): 156-164.	2021	Saudi Arabia	4	84	84	7
AlSheikh H, Ahmad Z, Johnson SR. Ethnic variations in systemic sclerosis disease manifestations, internal organ involvement, and mortality. *JRheumatol* 2019: 46(9): 1103-1108.	2019	Canada	2	1005	349	8
Amoura Z, Duhaut P, Huong DLT, Wechsler B, Costedoat-Chalumeau N, Frances C, Cacoub P, Papo T, Cormont S, Touitou Y, Grenier P, Valeyre D, Piette J-C. Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. *Cancer EpidemiolBiomarkers Prev* 2005: 14(5): 1279-1282.	2005	France	3	102	26	8
Ananyeva I, Teplova LV, Lesnyak VN, Starovojtova MN, Desinova OV, Nevskaya TA. Relationship between computed tomography and lung function parameters in patients with different duration of systemic sclerosis. In; 2010 2010: (var.pagings). 28 (2 SUPPL. 58) (pp S151); Clinical and Experimental Rheumatology S.A.S.; 2010.	2010	Russia	2	138	113	8
Atienza-Mateo B, Remuzgo-Martinez S, Cuesta VMM, Iturbe-Fernandez D, Fernandez-Rozas S, Prieto-Pena D, Calderon-Goercke M, Corrales A, Rodriguez GB, Gomez-Roman JJ, Gonzalez-Gay MA, Cifrian JM. The spectrum of interstitial lung disease associated with autoimmune diseases: Data of a 3.6-year prospective study from a referral center of interstitial lung disease and lung transplantation. *J Clin Med* 2020: 9(6): 1606.	2020	Spain	1, 2	89	89	7

Atukorala I, Solangaarachchi C, Weeratunga PN, Wijayaratne LS, Weerasekera L. Rheumatoid lung disease and tuberculosis in a cohort of Sri Lankan patients with Rheumatoid Arthritis. In; 2012 2012: (var.pagings). 15 (SUPPL. 1) (pp 51); Blackwell Publishing; 2012.	2012	Sri Lanka	1	231	12	6
Aubart F, Crestani B, NicaiseRoland P, Tubach F, Bollet C, Dawidowicz K, Quintin E, Hayem G, Palazzo E, Meyer O, CholletMartin S, Dieude P. High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis. *JRheumatol* 2011: 38(6): 979-982.	2011	France	1	252	23	6
Avouac J, Airo P, Dieude P, Caramaschi P, Tiev K, Diot E, Sibilia J, Cappelli S, Granel B, Vacca A, Wipff J, Meyer O, Kahan A, MatucciCerinic M, Allanore Y. Associated autoimmune diseases in systemic sclerosis define a subset of patients with milder disease: Results from 2 large cohorts of European Caucasian patients. *JRheumatol* 2010: 37(3): 608-614.	2010	France, Italy	2	1132	395	8
Avouac J, Cauvet A, Steelandt A, Shirai Y, Elhai M, Kuwana M, Distler O, Allanore Y. Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease. *PloS one* 2020: 15(5): e0232978.	2020	Germany	1	40	40	9
Azuma K, Yamada H, Ohkubo M, Yamasaki Y, Yamasaki M, Mizushima M, Ozaki S. Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis. *Modern Rheumatology* 2011: 21(2): 178-183.	2011	Japan	3	136	73	8

Bagnato G, Pigatto E, Bitto A, Pizzino C, Irrera N, Abignano G, Hutchinson M, Squadrito F, Buch MH, Gangemi S, Roberts WN, Saitta A, Cozzi F, Del Galdo F. Predictive value of a combined index for weight loss in systemic sclerosis. In; 2017 2017: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 2017. United States. 69 (Supplement 10) (no pagination); John Wiley and Sons Inc.; 2017.	2017	UK, Italy	2	180	64	6
Baillieau NA, Tabaj G, Villagomez R, Di Boscio V, Quadrelli SA. Computed tomography characteristics and five-year survival in patients with systemic sclerosis. In; 2010 2010: (var.pagings). 138 (4) (no pagination); American College of Chest Physicians; 2010.	2010	Argentina	2	70	40	7
Balanescu P, Balanescu E, Baicus C, Balanescu A. S100A6, Calumenin and Cytohesin 2 as Biomarkers for Cutaneous Involvement in Systemic Sclerosis Patients: A Case Control Study. *J pers med* 2021: 11(5).	2021	Romania	2	53	28	7
Balcazar R, Brigante A, Maldonado F, Yucra D, Hamaui A, Dubinsky D. Capillaroscopic findings in patients with systemic sclerosis with and without lung involvement. In; 2019 2019: 21st Pan American Rheumatology Congress, PANLAR 2019. Ecuador. 25 (3 Supplement) (pp S91); Lippincott Williams and Wilkins; 2019.	2019	Argentina	2	58	22	7
Baldini C, Puxeddu I, Orlandi M, Ferro F, Elefante E, Luciano N, MatucciCerinic M, Migliorini P, Mosca M. Interstitial lung disease in primary sjogren's syndrome : Clinical presentation, serological biomarkers and long term outcome. In; 2017 2017: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 2017. United States. 69 (Supplement 10) (no pagination); John Wiley and Sons Inc.; 2017.	2017	Italy	4	285	18	7

Ballerie A, Cavalin C, Lederlin M, Nicolas A, Garlantezec R, Jouneau S, Lecureur V, Cazalets C, Belhomme N, Paris C, Rosental P-A, Jego P, Lescoat A. Association of silica exposure with chest HRCT and clinical characteristics in systemic sclerosis. *Semin Arthritis Rheum* 2020: 50(5): 949-956.	2020	France	2	97	31	8
Benyamine A, Heim X, Resseguier N, Bertin D, Gomez C, Ebbo M, Harle J-R, Kaplanski G, Rossi P, Bardin N, Granel B. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease. *RheumatolInt* 2018: 38(5): 813-819.	2018	Germany	2	75	25	5
Best M, Jachiet M, Molinari N, Manna F, Girard C, Pallure V, Cosnes A, Lipsker D, Hubiche T, Schmutz JL, Le Corre Y, Cordel N, Dandurand M, Dereure O, Guillot B, DuThanh A, Bulai Livideanu C, Chasset F, Bouaziz JD, Frances C, Bengoufa D, Vincent T, Bessis D. Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients. *Journal of the European Academy of Dermatology and Venereology* 2018: 32(7): 1164-1172.	2018	France	3	117	17	7
Bhansing KJ, Lammens M, Knaapen HKA, van Riel PLCM, van Engelen BGM, Vonk MC. Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: a descriptive study on clinical features and myopathology. *Arthritis Research & Therapy* 2014: 16(3): R111.	2014	Netherlands	2	397	170	8
Bo L, LiMing C, CuiLi M, Ping L, LiQi B. Study on rheumatoid arthritis-associated interstitial lung disease in the elderly patients. In; 2012 2012: (var.pagings). 15 (SUPPL. 1) (pp 49); Blackwell Publishing; 2012.	2012	China	1	565	50	8

Bocchino M, Bruzzese D, D'Alto M, Argiento P, Borgia A, Capaccio A, Romeo E, Russo B, Sanduzzi A, Valente T, Sverzellati N, Rea G, Vettori S. Performance of a new quantitative computed tomography index for interstitial lung disease assessment in systemic sclerosis. *Scientific Reports* 2019: 9(1): 9468.	2018	Italy	2	83	39	8
Bodolay E, Szekanecz Z, Devenyi K, Galuska L, Csipo I, Vegh J, Garai I, Szegedi G. Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). *Rheumatology* 2005: 44(5): 656-661.	2005	Hungary	5	144	96	8
Buvry C, Cassagnes L, Tekath M, Artigues M, Pereira B, Rieu V, Le Guenno G, Tournadre A, Ruivard M, Grobost V. Anti-Ro52 antibodies are a risk factor for interstitial lung disease in primary Sjogren syndrome. *Respiratory medicine* 2020: 163(8908438, rme): 105895.	2020	France	4	68	19	6
Caimmi C, Bertoldo E, Venturini A, Caramaschi P, Frulloni L, Ciccocioppo R, Brunelli S, Idolazzi L, Gatti D, Viapiana O, Rossini M. Interstitial lung disease is independently associated with increased fecal calprotectin levels in systemic sclerosis. In; 2018 2018: 5th Systemic Sclerosis World Congress. France. 3 (Supplement 1) (pp 94); SAGE Publications Inc.; 2018.	2018	Italy	2	129	35	7
Callejas-Moraga EL, Guillen-Del-Castillo A, Perurena-Prieto J, Sanz-Martinez MT, Fonollosa-Pla V, Lorite-Gomez K, Severino A, Bellocchi C, Beretta L, Mahler M, Simeon-Aznar CP. Anti-RNPC-3 antibody predicts poor prognosis in patients with interstitial lung disease associated to systemic sclerosis. *Rheumatology (Oxford)* 2021: 61(1): 154-162.	2022	Spain, Italy	2	447	155	9
Can G, Sarioglu S, Birlik M, Kenar G, Soysal O, Solmaz D, Gerdan V, Onen F, Akkoc N, Akar S. The prevalence of sjogren's syndrome and sicca symptoms in patients with systemic sclerosis and alpha-smooth muscle actin expression in biopsy specimens from minor salivary glands. *Turk J Med Sci* 2021: 51(4): 1875-1882.	2021	Turkey	2	102	35	8

Castellanos-Moreira R, Rodriguez-Garcia SC, Gomara MJ, Ruiz-Esquide V, Cuervo A, Casafont-Sole I, Ramirez J, Holgado S, Gomez-Puerta JA, Canete JD, Haro I, Sanmarti R. Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: evidence of a new autoantibody linked to interstitial lung disease. *Annals of the Rheumatic Diseases* 2020(Journal Article).	2020	Spain	1	179	37	7
Chan C, Ryerson CJ, Dunne JV, Wilcox PG. Demographic and clinical predictors of progression and mortality in connective tissue disease-associated interstitial lung disease: a retrospective cohort study. *BMC Pulmonary Medicine* 2019: 19(1): 192.	2019	Canada	1, 2, 5	359	359	9
Chan E, Kelly C, Woodhead FA, Nisar M, Arthanari S, Dawson J, Sathi N, Ahmad Y, Koduri G, Young A. Ra-related interstitial lung disease: Which factors predict its development? In; 2013 2013: (var.pagings). 52 (SUPPL. 1) (pp i75); Oxford University Press; 2013.	2013	UK	1	230	230	7
Chen J, Doyle TJ, Liu Y, Aggarwal R, Wang X, Shi Y, Ge SX, Huang H, Lin Q, Liu W, Cai Y, Koontz D, Fuhrman CR, Golzarri MF, Liu Y, Hatabu H, Nishino M, Araki T, Dellaripa PF, Oddis CV, Rosas IO, Ascherman DP. Biomarkers of rheumatoid arthritis-associated interstitial lung disease. *Arthritis rheumatol* 2015: 67(1): 28-38.	2015	USA	1	133	41	8
Chen J, Shi Y, Wang X, Huang H, Ascherman D. Asymptomatic preclinical rheumatoid arthritis-associated interstitial lung disease. *ClinDevImmunol* 2013: 2013(Journal Article): 406927.	2013	China	1	103	63	7
Chen J, Song S, Liu Y, Liu D, Lin Y, Ge S, Ascherman DP. Autoreactive T cells to citrullinated HSP90 are associated with interstitial lung disease in rheumatoid arthritis. *International Journal of Rheumatic Diseases* 2018: 21(7): 1398-1405.	2018	China	1	66	24	7

Chen Q, Chen D-Y, Xu X-Z, Liu Y-Y, Yin T-T, Li D. Platelet/Lymphocyte, Lymphocyte/Monocyte, and Neutrophil/Lymphocyte Ratios as Biomarkers in Patients with Rheumatoid Arthritis and Rheumatoid Arthritis-Associated Interstitial Lung Disease. *MedSciMonit* 2019: 25(Journal Article): 6474-6481.	2019	China	1	301	103	7
Chua F, Higton AM, Colebatch AN, O'Reilly K, Grubnic S, Vlahos I, Edwards CJ, Kiely PDW. Idiopathic inflammatory myositis-associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort. *Rheumatology* 2012: 51(10): 1870-1876.	2012	UK	3	107	40	7
Chua F, Higton AM, McNulty K, Grubnic S, Edwards EJ, Kiely PDW. Interstitial lung disease in the inflammatory myositides: Exacerbations of muscle disease are not paralleled by worsening of pulmonary function. In; 2009 2009: (var.pagings). 64 (SUPPL. 4) (pp A5-A6); BMJ Publishing Group; 2009.	2009	UK	3	47	20	7
Coath F, Siddiqui S, Himashi A, Bharadwaj A, Dubey S, Hayes F, Koduri G. Does the presence of ILD influence the choice of DMARD and biologic therapy in rheumatoid arthritis? In; 2018 2018: Annual European Congress of Rheumatology, EULAR 2018. Netherlands. 77 (Supplement 2) (pp 1345); BMJ Publishing Group; 2018.	2018	Not Stated	1	37	37	7
Cobo-Ibanez T, Lopez-Longo F-J, Joven B, Carreira PE, Munoz-Fernandez S, Maldonado-Romero V, Larena-Grijalba C, Cubas IL, Muriel ET, Mateos CB, de la Pena Lefebvre PG, Gomez-Gomez A, Nogal LB, Perez A, Almodovar R, Lojo L, Ruiz-Gutierrez L, Lopez-Robledillo JC, Garcia de Yebenes MJ, Nuno-Nuno L. Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease. *Clinical rheumatology* 2019: 38(3): 803-815.	2018	Spain	3	478	129	8

Cozzi F, Guarnieri G, Zanatta E, Pigatto E, Favaro M, Cardarelli S, Maestrelli P, Punzi L. Capillary blood volume measurement in scleroderma patients submitted to nitric oxide diffusion test. In; 2012 2012: (var.pagings). 51 (SUPPL. 2) (pp ii104); Oxford University Press; 2012.	2012	Italy	2	37	12	7
D'Andrea A, D'Alto M, Di Maio M, Vettori S, Benjamin N, Cocchia R, Argiento P, Romeo E, Di Marco G, Russo MG, Valentini G, Calabro R, Bossone E, Grunig E. Right atrial morphology and function in patients with systemic sclerosis compared to healthy controls: a two-dimensional strain study. *Clinical rheumatology* 2016: 35(7): 1733-1742.	2016	Germany	2	90	48	7
Daldoul C, El Amri N, Guiga A, Laataoui S, Baccouche K, Zegaloui H, Bouajina E. Usual interstitial pneumonia during rheumatoid arthritis: Prevalence and associated factors. *Annals of the Rheumatic Diseases* 2021: 80(SUPPL 1): 526-527.	2021	Tunisia	1	59	33	9
Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. *Thorax* 2001: 56(8): 622-627.	2001	UK	1	150	28	7
De Santis M, Bosello SL, Peluso G, Pinnelli M, Alivernini S, Zizzo G, Bocci M, Capacci A, La Torre G, Mannocci A, Pagliari G, Varone F, Pistelli R, Danza FM, Ferraccioli G. Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease. *ClinRespirJ* 2012: 6(1): 9-17.	2012	Italy	2	110	73	7
Debray MP, Borie R, Revel MP, Naccache JM, Khalil A, Toper C, IsraelBiet D, Estellat C, Brillet PY. Interstitial lung disease in anti-synthetase syndrome: Initial and follow-up CT findings. *EurJRadiol* 2015: 84(3): 516-523.	2015	France	3	33	33	8

Del Angel-Pablo AD, Buendia-Roldan I, Mejia M, Perez-Rubio G, Nava-Quiroz KJ, Rojas-Serrano J, Falfan-Valencia R. Anti-HLA Class II Antibodies Correlate with C-Reactive Protein Levels in Patients with Rheumatoid Arthritis Associated with Interstitial Lung Disease. *Cells* 2020: 9(3).	2020	Mexico	1	147	65	7
Dobrota I, Petcu A, Rednic S. Pulmonary involvement in SSc patients - A single centre experience. In; 2014 2014: (var.pagings). 32 (2 SUPPL. 81) (pp S85); Clinical and Experimental Rheumatology S.A.S.; 2014.	2014	Romania	2	42	33	7
Duarte AC, Porter JC, Leandro MJ. The lung in a cohort of rheumatoid arthritis patients-an overview of different types of involvement and treatment. *Rheumatology (United Kingdom)* 2019: 58(11): 2031-2038.	2019	UK	1	1129	45	7
Elhai M, Hoffmann-Vold AM, Avouac J, Pezet S, Cauvet A, Leblond A, Fretheim H, Garen T, Kuwana M, Molberg O, Allanore Y. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease. *Arthritis rheumatol* 2019: 71(6): 972-982.	2019	France	2	427	234	8
Emilie S, Goulvestre C, Berezne A, Pagnoux C, Guillevin L, Mouthon L. Anti-RNA polymerase III antibodies are associated with scleroderma renal crisis in a French cohort. *Scandinavian journal of rheumatology* 2011: 40(5): 404-406.	2011	France	2	195	70	7
Enomoto N, Egashira R, Tabata K, Hashisako M, Kitani M, Waseda Y, Ishizuka T, Watanabe S, Kasahara K, Izumi S, Shiraki A, Miyamoto A, Kishi K, Kishaba T, Sugimoto C, Inoue Y, Kataoka K, Kondoh Y, Tsuchiya Y, Baba T, Sugiura H, Tanaka T, Sumikawa H, Suda T. Analysis of systemic lupus erythematosus-related interstitial pneumonia: a retrospective multicentre study. *Scientific Reports* 2019: 9(1): 7355.	2019	Japan	6	55	55	7

Eroglu DS, Colaklar A, Baysal S, Torgutalp M, Baygul A, Sezer S, Guloksuz EA, Yuksel M, Yayla M, Yurteri EU, Uzun C, Kumbasar OO, Turgay M, Gulay K, Ates A. Prevalence and predictors of mortality in rheumatoid arthritis-related lung disease: Results from a single center study. *Arthritis Rheum* 2021: 73(SUPPL 9): 590-592.	2021	Turkey	1	9756	107	7
Escola-Verge L, Pinal-Fernandez I, Fernandez-Codina A, Callejas-Moraga EL, Espinosa J, Marin A, Labrador-Horrillo M, Selva-O'Callaghan A. Mixed Connective Tissue Disease and Epitope Spreading: An Historical Cohort Study. *Jclinrheumatol* 2017: 23(3): 155-159.	2017	USA	5	40	10	7
Fadda S, Khairy N, Fayed H, Mousa H, Taha R. Interstitial lung disease in Egyptian patients with rheumatoid arthritis: Frequency, pattern and correlation with clinical manifestations and anti-citrullinated peptide antibodies level. *Egyptian Rheumatologist* 2018: 40(3): 155-160.	2017	Egypt	1	88	63	2
Fagundes MN, Caleiro MTC, NavarroRodriguez T, Baldi BG, Kavakama J, Salge JM, Kairalla R, Carvalho CRR. Esophageal involvement and interstitial lung disease in mixed connective tissue disease. *Respiratory medicine* 2009: 103(6): 854-860.	2009	Brazil	5	50	39	4
Fava A, Cimbro R, Wigley FM, Liu Q-R, Rosen A, Boin F. Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma. *Arthritis Research & Therapy* 2016: 18(1): 99.	2016	USA	2	27	11	5
Flores J, Baenas D, Riscanevo N, Saad E, Salinas MJH, Retamozo S, Alvarez AC, Alvarellos A, Pirola JP, Benzaquen N, Saurit V, Caeiro F. Lung involvement in primary Sjogren's syndrome: Spectrum of pulmonary abnormalities and computed tomography findings. In; 2018 2018: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 2018. United States. 70 (Supplement 9) (pp 2448-2449); John Wiley and Sons Inc.; 2018.	2018	Argentina	4	197	19	7

Font CV, Nieto MA, Leon L, RodriguezRodriguez L, Urgelles JF, Cour EP, Jover JA, Alcazar LA. Mortality and clinical features in rheumatoid arthritis and interstitial lung disease. In; 2017 2017: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 2017. United States. 69 (Supplement 10) (no pagination); John Wiley and Sons Inc.; 2017.	2017	Spain	1	31	31	6
Foocharoen C, Peansukwech U, Mahakkanukrauh A, Suwannaroj S, Pongkulkiat P, Khamphiw P, Nanagara R. Clinical characteristics and outcomes of 566 Thais with systemic sclerosis: A cohort study. *International journal of rheumatic diseases* 2020: 23(7): 945-957.	2020	Thailand	2	566	265	8
Fotoh DS, Helal A, Rizk MS, Esaily HA. Serum Krebs von den Lungen-6 and lung ultrasound B lines as potential diagnostic and prognostic factors for rheumatoid arthritis-associated interstitial lung disease. *Clinical rheumatology* 2021: 40(7): 2689-2697.	2021	Egypt	1	150	75	5
Fu Q, Zheng Y. Risk factors for progression and prognosis of rheumatoid arthritis-associated interstitial lung disease: Single centre study with a large sample of Chinese population. In; 2018 2018: Annual European Congress of Rheumatology, EULAR 2018. Netherlands. 77 (Supplement 2) (pp 1326); BMJ Publishing Group; 2018.	2018	China	1	266	266	9
Fui A, Bergantini L, Selvi E, Mazzei MA, Bennett D, Pieroni MG, Rottoli P, Bargagli E. Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis. *InternMedJ* 2020: 50(3): 330-336.	2019	Italy	1	28	28	5
Fujita Y, Asano T, Matsuoka N, Temmoku J, Sato S, Matsumoto H, Furuya MY, Suzuki E, Watanabe H, Kawakami A, Migita K. Differential regulation and correlation between galectin-9 and anti-CCP antibody (ACPA) in rheumatoid arthritis patients. *Arthritis research & therapy* 2020: 22(1): 80.	2020	Japan	1	116	31	6

Fukamatsu H, Hirai Y, Miyake T, Kaji T, Morizane S, Yokoyama E, Hamada T, Oono T, Koyama Y, Norikane S, Iwatsuki K. Clinical manifestations of skin, lung and muscle diseases in dermatomyositis positive for anti-aminoacyl tRNA synthetase antibodies. *JDermatol* 2019: 46(10): 886-897.	2019	Japan	3	59	27	4
Gao M-Z, Wei Y-Y, Xu Q-W, Ji R, Han Z-J, Jiang T-W. Elevated serum YKL-40 correlates with clinical characteristics in patients with polymyositis or dermatomyositis. *AnnClinBiochem* 2019: 56(1): 95-99.	2019	China	5	99	23	6
Gautam M, Masood MJ, Arooj S, Mahmud M-EH, Mukhtar MU. Rheumatoid Arthritis Related Interstitial Lung Disease: Patterns of High-resolution Computed Tomography. *Cureus* 2020: 12(2): e6875.	2020	Pakistan	1	54	25	3
Giles JT, Danoff SK, Sokolove J, Wagner CA, Winchester R, Pappas DA, Siegelman S, Connors G, Robinson WH, Bathon JM. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. *Annals of the Rheumatic Diseases* 2014: 73(8): 1487-1494.	2014	USA	1	177	57	6
Go DJ, Lee EY, Lee EB, Song YW, Konig MF, Park JK. Elevated Erythrocyte Sedimentation Rate Is Predictive of Interstitial Lung Disease and Mortality in Dermatomyositis: a Korean Retrospective Cohort Study. *JKorean MedSci* 2016: 31(3): 389-396.	2016	South Korea	3	114	53	7
Gonzalez Fernandez I, Moriano C, Diez Alvarez E, Larco Rojas XE, Lopez Robles A, Vallejo Pascual ME, Perez Sandoval MT. Interstitial lung involvement in systemic lupus erythematosus: Relevant clinical characteristics. Our experience in a third level hospital. *Annals of the Rheumatic Diseases* 2021: 80(SUPPL 1): 628-629.	2021	Spain	6	455	20	8
Guiot J, Njock M-S, Andre B, Gester F, Henket M, de Seny D, Moermans C, Malaise MG, Louis R. Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction. *Scientific reports* 2021: 11(1): 10882.	2021	Belgium	2	102	39	6

Gunther F, Straub RH, Hartung W, Luchner A, Fleck M, Ehrenstein B. Increased Serum Levels of soluble ST2 as a Predictor of Disease Progression in Systemic Sclerosis. *Scandinavian journal of rheumatology* 2022: 51(4): 315-322.	2022	Germany	2	49	25	7
Hall JC, Casciola-Rosen L, Samedy L-A, Werner J, Owoyemi K, Danoff SK, Christopher-Stine L. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. *Arthritis CareRes(Hoboken)* 2013: 65(8): 1307-1315.	2013	USA	3	160	25	5
Hanaka T, Kido T, Ishimoto H, Oda K, Noguchi S, Nawata A, Nakayamada S, Sakamoto N, Tanaka Y, Yatera K, Mukae H. Radiological patterns of pulmonary involvement may predict treatment response in rheumatoid arthritis: A retrospective study. *RespirInvestig* 2019: 57(2): 172-182.	2019	Japan	1	77	77	7
Hax V, Bredemeier M, Didonet Moro AL, Pavan TR, Vieira MV, Pitrez EH, da Silva Chakr RM, Xavier RM. Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis. *SeminArthritis Rheum* 2017: 47(2): 228-234.	2017	Brazil	2	177	101	6
Hayashi S, Tanaka M, Kobayashi H, Nakazono T, Satoh T, Fukuno Y, Aragane N, Tada Y, Koarada S, Ohta A, Nagasawa K. High-resolution computed tomography characterization of interstitial lung diseases in polymyositis/dermatomyositis. *JRheumatol* 2008: 35(2): 260-269.	2007	Japan	3	55	33	8
Hizal M, Bruni C, Romano E, Mazzotta C, Guiducci S, Bellando Randone S, Blagojevic J, Lepri G, Tufan A, Matucci Cerinic M. Decrease of LL-37 in systemic sclerosis: a new marker for interstitial lung disease? *Clinical rheumatology* 2015: 34(4): 795-798.	2015	Italy	2	58	30	6

Hoang-Duc H, Pham-Huy Q, Vu-Minh T, Duong-Quy S. Study of the correlation between HRCT semi-quantitative scoring, concentration of alveolar nitric oxide, and clinical-functional parameters of systemic sclerosis-induced interstitial lung disease. *Yale J Biol Med* 2020: 93(5): 657-667.	2020	Vietnam	2	74	41	6
Hoffmann-Vold A-M, Fretheim H, Halse A-K, Seip M, Bitter H, Wallenius M, Garen T, Salberg A, Brunborg C, Midtvedt O, Lund MB, Aalokken TM, Molberg O. Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort. *AmJRespirCritCare Med* 2019: 200(10): 1258-1266.	2019	Norway	2	815	326	9
Hozumi H, Enomoto N, Kono M, Fujisawa T, Inui N, Nakamura Y, Sumikawa H, Johkoh T, Nakashima R, Imura Y, Mimori T, Suda T. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study. *PLoS ONE [Electronic Resource]* 2015: 10(3): e0120313.	2015	Japan	3	48	48	8
Hu S, Hou Y, Wang Q, Li M, Xu D, Zeng X. Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China. *Arthritis Research & Therapy* 2018: 20(1): 235.	2018	China	2	448	358	6
Iniesta Arandia N, Simeon-Aznar CP, Guillen Del Castillo A, Colunga Arguelles D, Rubio-Rivas M, Trapiella Martinez L, Garcia Hernandez FJ, Saez Comet L, Egurbide Arberas MV, Ortego-Centeno N, Freire M, Mari Alfonso B, Vargas Hitos JA, Rios Blanco JJ, Todoli Parra JA, Rodriguez-Carballeira M, Marin Ballve A, Chamorro Fernandez AJ, Pla Salas X, Madronero Vuelta AB, Ruiz Munoz M, Fonollosa Pla V, Espinosa G, Rescle investigators ADSG. Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis. *ClinExpRheumatol* 2017: 35(Suppl 106(4): 98-105.	2017	Spain	2	209	81	8

Ishizuka M, Watanabe R, Ishii T, Machiyama T, Akita K, Fujita Y, Shirota Y, Fujii H, Harigae H. Long-term follow-up of 124 patients with polymyositis and dermatomyositis: Statistical analysis of prognostic factors. *Modern Rheumatology* 2016: 26(1): 115-120.	2016	Japan	3	124	76	7
Izuka S, Yamashita H, Iba A, Takahashi Y, Kaneko H. Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: clinical features and prognosis. *Rheumatology (Oxford)* 2021: 60(5): 2348-2354.	2021	Japan	1	1325	165	7
Jacob J, Hirani N, van Moorsel CHM, Rajagopalan S, Murchison JT, van Es HW, Bartholmai BJ, van Beek FT, Struik MHL, Stewart GA, Kokosi M, Egashira R, Brun AL, Cross G, Barnett J, Devaraj A, Margaritopoulos G, Karwoski R, Renzoni E, Maher TM, Wells AU. Predicting outcomes in rheumatoid arthritis related interstitial lung disease. Eur Respir J 2019: 53(1)	2019	United Kingdom	1	157	157	9
Jantarat A, Muangchan C. Epidemiology and clinical characteristics of systemic sclerosis overlap syndrome (SSc-OS), and the factors significantly associated with SSc-OS in Thai patients with systemic sclerosis. *Modern rheumatology* 2021(100959226).	2021	Thailand	2	152	88	7
Jayasinghe P, Wickramasinghe N, Krishnakumar P, Sadikeen A, Fernando A. Characteristics of Connective Tissue Diseases Associated Interstitial Lung Diseases - A Single Centre Study in Sri Lanka. *Ceylon Med J* 2021: 66(1): 38-43.	2021	Sri Lanka	1, 2	83	75	9
Jinta T, Okada M, Ishikawa G, Yamano Y, Tomishima Y, Uchiyama N, Nishimura N, Chohnabayashi N. Interstitial lung disease in systemic sclerosis: A comparison between limited cutaneus systemic sclerosis and diffuse cutaneus systemic sclerosis. In; 2012 2012: (var.pagings). 185 (MeetingAbstracts) (no pagination); American Thoracic Society; 2012.	2012	Japan	2	157	64	1

Johnson C, Pinal Fernandez I, Paik J, Albayda M, Mammen A, ChristopherStine L, Danoff S. Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease. In; 2014 2014: (var.pagings). 189 (MeetingAbstracts) (no pagination); American Thoracic Society; 2014.	2016	USA	3	831	94	8
Juge P-A, Lee JS, Lau J, Kawano-Dourado L, Rojas Serrano J, Sebastiani M, Koduri G, Matteson E, Bonfiglioli K, Sawamura M, Kairalla R, Cavagna L, Bozzalla Cassione E, Manfredi A, Mejia M, Rodriguez-Henriquez P, Gonzalez-Perez MI, Falfan-Valencia R, Buendia-Roldan I, Perez-Rubio G, Ebstein E, Gazal S, Borie R, Ottaviani S, Kannengiesser C, Wallaert B, Uzunhan Y, Nunes H, Valeyre D, Saidenberg-Kermanac'h N, Boissier M-C, Wemeau-Stervinou L, Flipo R-M, Marchand-Adam S, Richette P, Allanore Y, Dromer C, Truchetet M-E, Richez C, Schaeverbeke T, Liote H, Thabut G, Deane KD, Solomon JJ, Doyle T, Ryu JH, Rosas I, Holers VM, Boileau C, Debray M-P, Porcher R, Schwartz DA, Vassallo R, Crestani B, Dieude P. Methotrexate and rheumatoid arthritis associated interstitial lung disease. *The European respiratory journal* 2021: 57(2).	2021	France, Italy, UK, Mexico, Brazil, US	1	1083	410	7
Juge PA, Wemeau L, MarchandAdam S, Debray MP, Nunes H, Gazal S, Ottaviani S, Schaeverbeke T, Saindenberg N, Valeyre D, Thabut G, Boissier MC, Dunogeant L, Allanore Y, Richez C, Flipo RM, Wallaert B, Richette P, Cottin V, Sibilia J, Borie R, Coustet B, Liote H, Soubrier M, Frazier A, Crestani B, Dieude P. Identification of markers associated with the occurrence of interstitial lung disease in rheumatoid arthritis patients. In; 2016 2016: Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR 2016. United Kingdom. 75 (Supplement 2) (pp 218); BMJ Publishing Group; 2016.	2016	France	1	253	138	4
Jung E, Suh C-H, Kim H-A, Jung J-Y. Clinical Characteristics of Systemic Sclerosis With Interstitial Lung Disease. *Archives of Rheumatology* 2018: 33(3): 322-327.	2018	Korea	2	108	43	6

Kakugawa T, Sakamoto N, Ishimoto H, Shimizu T, Nakamura H, Nawata A, Ito C, Sato S, Hanaka T, Oda K, Kido T, Miyamura T, Nakashima S, Aoki T, Nakamichi S, Obase Y, Saito K, Yatera K, Ishimatsu Y, Nakayama T, Korogi Y, Kawakami A, Tanaka Y, Mukae H. Lymphocytic focus score is positively related to airway and interstitial lung diseases in primary Sjogren's syndrome. *Respiratory medicine* 2018: 137(Journal Article): 95-102.	2018	Japan	4	101	32	6
Kang J, Kim H, Ahn GY, Jeong SA, Kim HW, Choi CB, Kim TH, Jun JB, Bae SC, Yoo D, Park DW, Sohn JW, Yoon HJ, Hong SJ, Choi YW, Lee Y, Kim SH, Cho SK, Sung YK. Establishment of a prospective cohort for rheumatoid arthritis patients with interstitial lung disease: Comparison of baseline characteristics between rheumatoid arthritis patient with or without interstitial lung disease. In; 2019 2019: Annual European Congress of Rheumatology, EULAR 2019. Spain. 78 (Supplement 2) (pp 2097-2098); BMJ Publishing Group; 2019.	2019	Not stated	1	313	74	5
Kang J, Seo WJ, Lee EY, Chang SH, Choe J, Hong S, Song JW. Pleuroparenchymal fibroelastosis in rheumatoid arthritis-associated interstitial lung disease. *Respir Res* 2022: 23(1): 143.	2022	Korea	1	477	477	8
Kawashiri S-Y, Nishino A, Igawa T, Takatani A, Shimizu T, Umeda M, Fukui S, Okada A, Suzuki T, Koga T, Iwamoto N, Ichinose K, Tamai M, Nakashima M, Mizokami A, Matsuoka N, Migita K, Ogawa F, Ikeda S, Maemura K, Nakamura H, Origuchi T, Maeda T, Kawakami A. Prediction of organ involvement in systemic sclerosis by serum biomarkers and peripheral endothelial function. *ClinExpRheumatol* 2018: 36(Suppl 113(4): 102-108.	2018	Japan	2	60	24	7

Kelly C, Chan E, Nisar M, Arthanari S, Woodhead F, Dawson J, Sathi N, Ahmad Y. Rheumatoid arthritis related interstitial lung disease-relevance of lung function tests and high resolution computed tomography in a large multi centre series. In; 2013 2013: (var.pagings). 72 (SUPPL. 3) (no pagination); BMJ Publishing Group; 2013.	2013	United Kingdom	1	159	159	3
Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, PriceForbes AN, Dawson J, Sathi N, Ahmad Y, Koduri G, Young A. Rheumatoid arthritis-related interstitial lung disease: Associations, prognostic factors and physiological and radiological characteristics-a large multicentre UK study. *Rheumatology (United Kingdom)* 2014: 53(9) (pp 1676-1682): Arte-Number: keu165. ate of Pubaton: Setember 2014.	2014	United Kingdom	1	460	230	7
Kim EJ, Elicker BM, Maldonado F, Webb WR, Ryu JH, Van Uden JH, Lee JS, King Jr TE, Collard HR. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. *European Respiratory Journal* 2010: 35(6): 1322-1328.	2010	USA	1	82	82	6
Kim YJ, Choe J, Kim HJ, Song JW. Long-term clinical course and outcome in patients with primary Sjogren syndrome-associated interstitial lung disease. *Scientific reports* 2021: 11(1): 12827.	2021	Korea	4	62	62	8
Klester E, Klester K, Shoykhet Y, Elykomov V, Yarkova V, Berdyugina A, Mukhtarova E. Risk factors of interstitial lung diseases in patients with rheumatoid arthritis. In; 2019 2019: 29th International Congress of the European Respiratory Society, ERS. Spain. 54 (Supplement 63) (no pagination); European Respiratory Society; 2019.	2019	Russia	1	167	26	4

Kondoh Y, Johkoh T, Fukuoka J, Arakawa H, Tanaka T, Watanabe N, Sakamoto K, Kataoka K, Kimura T, Taniguchi H. Broader criteria of undifferentiated connective tissue disease in idiopathic interstitial pneumonias. *Respiratory medicine* 2015: 109(3): 389-396.	2015	Japan	7	24	24	4
Kronzer VL, Huang W, Dellaripa PF, Huang S, Feathers V, Lu B, Iannaccone CK, Gill RR, Hatabu H, Nishino M, Crowson CS, Davis JM, 3rd, Weinblatt ME, Shadick NA, Doyle TJ, Sparks JA. Lifestyle and Clinical Risk Factors for Incident Rheumatoid Arthritis-associated Interstitial Lung Disease. *J Rheumatol* 2021: 48(5): 656-663.	2021	USA	1	317	84	7
Kubo S, Siebuhr AS, Bay-Jensen A-C, Juhl P, Karsdal MA, Satoh Y, Todoroki Y, Nakano K, Nakayamada S, Tanaka Y. Correlation between serological biomarkers of extracellular matrix turnover and lung fibrosis and pulmonary artery hypertension in patients with systemic sclerosis. *International Journal of Rheumatic Diseases* 2020(Journal Article).	2020	Japan	2	79	37	4
KurZalewska J, Tlustochowicz M, Tlustochowicz W. Risk factors of interstitial lung disease in patients with rheumatoid arthritis. In; 2013 2013: (var.pagings). 71 (SUPPL. 3) (no pagination); BMJ Publishing Group; 2013.	2013	Poland	1	111	53	6
Lai N-L, Jia W, Wang X, Luo J, Liu G-Y, Gao C, Li X-F, Xie J-F. Risk Factors and Changes of Peripheral NK and T Cells in Pulmonary Interstitial Fibrosis of Patients with Rheumatoid Arthritis. *CanRespirJ* 2019: 2019(Journal Article): 7262065.	2019	China	1	200	100	6
Lee JS, Ghang B, Choi W, Hong S, Kim Y-G, Lee C-K, Nam SJ, Yoo B. Expression of Inflammatory Markers in the Muscles of Patients with Idiopathic Inflammatory Myopathy According to the Presence of Interstitial Lung Disease. *J Clin Med* 2022: 11(11).	2022	Korea	3	129	49	8

Lee K-A, Choi W, Kim J, Lee S-H, Kim H-R, Kim H-S. Elderly-onset primary Sjogren's syndrome focused on clinical and salivary gland ultrasonographic features. *Joint Bone Spine* 2021: 88(4): 105132.	2021	Korea	4	221	43	7
Li L, Liu R, Zhang Y, Zhou J, Li Y, Xu Y, Gao S, Zheng Y. A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease. *Clinical rheumatology* 2019(Journal Article).	2019	China	1	923	278	9
Li L, Wang H, Wang Q, Wu C, Liu C, Zhang Y, Cheng L, Zeng X, Zhang F, Li Y. Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease. *JNeurolSci* 2019: 397(Journal Article): 123-128.	2019	China	3	130	79	4
Li X, Wang Y. Soluble CD163 levels are elevated in patients with rheumatoid athritis and associated with interstitial lung disease. In; 2016 2016: 18th Asia Pacific League of Associations for Rheumatology Congress, APLAR. China. 19 (Supplement 2) (pp 200); Blackwell Publishing; 2016.	2016	China	1	66	34	4
Liu L, Fang C, Sun B, Bao R, Zhang H. Predictors of progression in rheumatoid arthritis-associated interstitial lung disease: A single-center retrospective study from China. *International journal of rheumatic diseases* 2022(101474930).	2022	China	1	201	201	7
Liu Z, Li M, Wang Q, Zhao Y, Xu D, Zeng X. The risk factors and prognosis of interstitial lung disease associated with primary sjogren's syndrome: A multi-center cohort study. In; 2018 2018: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 2018. United States. 70 (Supplement 9) (pp 1733-1734); John Wiley and Sons Inc.; 2018.	2018	China	4	1184	184	5

Manetti M, Guiducci S, Romano E, Bellando-Randone S, Conforti ML, Ibba-Manneschi L, Matucci-Cerinic M. Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage. *Annals of the Rheumatic Diseases* 2012: 71(6): 1064-1072.	2012	Italy	2	72	34	7
Manfredi A, Sebastiani M, Cerri S, Della Casa G, Giuggioli D, Vacchi C, Colaci M, Spinella A, Luppi F, Ferri C. Unclassifiable interstitial lung disease or undifferentiated connective tissue disease? A challenging differential diagnosis. In; 2015 2015: (var.pagings). 74 (SUPPL. 2) (pp 591); BMJ Publishing Group; 2015.	2015	Italy	7	26	26	6
Manfredi A, Vacchi C, DellaCasa G, Cerri S, Cassone G, Di Cecco G, Luppi F, Salvarani C, Sebastiani M. Fibrosing interstitial lung disease in primary Sjogren syndrome. *Joint Bone Spine* 2021: 88(6): 105237.	2021	Italy	4	34	34	8
Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: A series of 107 patients. *Arthritis Rheum* 2011: 63(11): 3439-3447.	2011	France	3	348	107	6
Marie I, Josse S, Decaux O, Dominique S, Diot E, Landron C, Roblot P, Jouneau S, Hatron PY, Tiev KP, Vittecoq O, Noel D, Mouthon L, Menard JF, Jouen F. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. *Autoimmunity Reviews* 2012: 11(10): 739-745.	2012	France	3	95	69	6

Markusse IM, Meijs J, de Boer B, Bakker JA, Schippers HPC, Schouffoer AA, Ajmone Marsan N, Kroft LJM, Ninaber MK, Huizinga TWJ, de Vries-Bouwstra JK. Predicting cardiopulmonary involvement in patients with systemic sclerosis: complementary value of nailfold videocapillaroscopy patterns and disease-specific autoantibodies. *Rheumatology* 2017: 56(7): 1081-1088.	2017	Netherlands	2	287	147	5
Martins Rocha T, Fonseca R, RosaGoncalves D, Aguiar F, Meirinhos T, Bernardes M, Bernardo A, Costa L. Anti-SSA/RO antibodies in a cohort of systemic sclerosis patients: The association with interstitial lung disease. In; 2016 2016: Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR 2016. United Kingdom. 75 (Supplement 2) (pp 1125); BMJ Publishing Group; 2016.	2016	Portugal	2	108	24	5
Mei YJ, Wang P, Jiang C, Wang T, Chen LJ, Li ZJ, Pan HF. Clinical and serological associations of anti-ribosomal P0 protein antibodies in systemic lupus erythematosus. *Clinical rheumatology* 2018: 37(3): 703-707.	2018	China	6	470	65	4
Mena-Vazquez N, Jimenez-Nunez FG, Godoy-Navarrete FJ, Manrique-Arija S, Aguilar-Hurtado MC, Romero-Barco CM, Urena-Garnica I, Espildora F, Padin-Martin MI, Fernandez-Nebro A. Utility of pulmonary ultrasound to identify interstitial lung disease in patients with rheumatoid arthritis. *Clinical rheumatology* 2021: 40(6): 2377-2385.	2021	Spain	1	71	35	8
Mena-Vazquez N, Perez Albaladejo L, Manrique-Arija S, Romero Barco CM, Gomez Cano C, Urena Garnica I, Fernandez-Nebro A. Analysis of Clinical-Analytical Characteristics in Patients with Rheumatoid Arthritis and Interstitial Lung Disease: Case-Control Study. *Reumatologia Clinica* 2019(Journal Article).	2019	Spain	1	82	41	8

Mena-Vazquez N, Rojas-Gimenez M, Romero-Barco CM, Manrique-Arija S, Hidalgo Conde A, Arnedo Diez de Los Rios R, Cabrera Cesar E, Ortega-Castro R, Espildora F, Aguilar-Hurtado MC, Anon-Onate I, Perez-Albaladejo L, Abarca-Costalago M, Urena-Garnica I, Velloso-Feijoo ML, Redondo-Rodriguez R, Fernandez-Nebro A. Characteristics and Predictors of Progression Interstitial Lung Disease in Rheumatoid Arthritis Compared with Other Autoimmune Disease: A Retrospective Cohort Study. *Diagnostics (Basel)* 2021: 11(10).	2021	Spain	1, 2, 3	204	204	8
Meune C, Avouac J, Airao P, Beretta L, Dieude P, Wahbi K, Caramaschi P, Tiev K, Cappelli S, Diot E, Vacca A, Cracowski JL, Sibilia J, Kahan A, MatucciCerinic M, Allanore Y. Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. *Arthritis Rheum* 2011: 63(9): 2790-2796.	2011	France	2	1165	401	4
Mok MY, Fung PCW, Ooi C, Tse HF, Wong Y, Lam YM, Wong WS, Lau CS. Serum nitric oxide metabolites and disease activity in patients with systemic sclerosis. *Clinical rheumatology* 2008: 27(3): 315-322.	2008	China	2	43	37	6
Mori S, Koga Y, Sugimoto M. Small airway obstruction in patients with rheumatoid arthritis. *Modern Rheumatology* 2011: 21(2): 164-173.	2011	Japan	1	189	19	7
Mori S, Koga Y, Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. *Respiratory medicine* 2012: 106(11): 1591-1599.	2012	Japan	1	356	24	7
Narang NS, Casciola-Rosen L, Li S, Chung L, Fiorentino DF. Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease. *Arthritis CareRes(Hoboken)* 2015: 67(5): 667-672.	2015	USA	3	152	29	7

Narula N, Narula T, Wang B, Abril A. Clinical predictors for development of interstitial lung disease in mixed connective tissue disease. In; 2016 2016: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 2016. United States. 68 (Supplement 10) (pp 3854); John Wiley and Sons Inc.; 2016.	2016	USA	5	28	14	9
Narvaez J, Borrell H, Sanchez-Alonso F, Rua-Figueroa I, Lopez-Longo FJ, Galindo-Izquierdo M, Calvo-Alen J, Fernandez-Nebro A, Olive A, Andreu JL, Martinez-Taboada V, Nolla JM, Pego-Reigosa JM, Group RS. Primary respiratory disease in patients with systemic lupus erythematosus: data from the Spanish rheumatology society lupus registry (RELESSER) cohort. *Arthritis Research & Therapy* 2018: 20(1): 280.	2018	Spain	6	3215	65	7
Nicholson TW, Woods A, David J, Hoyles R. Anti-synthetase syndrome: Validity of ana as a screening tool-the oxford ild service experience. In; 2014 2014: (var.pagings). 69 (SUPPL. 2) (pp A193-A194); BMJ Publishing Group; 2014.	2014	UK	3	24	24	9
Nieto MA, Rodriguez-Nieto MJ, Sanchez-Pernaute O, Romero-Bueno F, Leon L, Vadillo C, Freites-Nunez DD, Jover JA, Alvarez-Sala JL, Abasolo L. Mortality rate in rheumatoid arthritis-related interstitial lung disease: the role of radiographic patterns. *BMC pulmonary medicine* 2021: 21(1): 205.	2021	Spain	1	47	47	8
Nihtyanova SI, Ong VH, Denton CP. Gender-associated differences in disease characteristics and outcome in systemic sclerosis. In; 2012 2012: (var.pagings). 64 (SUPPL. 10) (pp S635); John Wiley and Sons Inc.; 2012.	2012	UK	2	398	207	8
Nikiphorou E, Chan E, Saravanan V, Dawson J, Sathi N, Woodhead F, Nisar M, Arthanari S, Ahmad Y, Young A, Kelly C. Serological biomarkers for the development of rheumatoid arthritis related interstitial lung disease. In; 2013 2013: (var.pagings). 65 (SUPPL. 10) (pp S182); John Wiley and Sons Inc.; 2013.	2013	UK	1	230	230	6

Nokes BT, Raza HA, Cartin-Ceba R, Lyng PJ, Krahn LE, Wesselius L, Jokerst CE, Umar SB, Griffing WL, Neville MR, Malhotra A, Parish JM. Individuals With Scleroderma May Have Increased Risk of Sleep-Disordered Breathing. *JClinSleep Med* 2019: 15(11): 1665-1669.	2019	USA	2	171	63	7
Nunez A, Ojanguren I, Munoz X, Cruz MJ, Morell F, Villar A. Radiologic pattern as a survival predictor in the rheumatoid artritis intersticial lung disease. In; 2015 2015: (var.pagings). 46 (SUPPL. 59) (no pagination); European Respiratory Society; 2015.	2015	Spain	1	21	21	7
Obert J, Freynet O, Nunes H, Brillet P-Y, Miyara M, Dhote R, Valeyre D, Naccache J-M. Outcome and prognostic factors in a French cohort of patients with myositis-associated interstitial lung disease. *RheumatolInt* 2016: 36(12): 1727-1735.	2016	France	3	48	48	8
Okada H, Kurasawa K, Yamazaki R, Tanaka A, Arai S, Owada T, Maezawa R, Ishii Y. Clinical features of organizing pneumonia associated with rheumatoid arthritis. *Modern Rheumatology* 2016: 26(6): 863-868.	2016	Japan	1	499	84	7
Oliveira RP, Ribeiro R, Melo L, Grima B, Oliveira S, Alves JD. Connective tissue disease-associated interstitial lung disease. *Pulmonology* 2022: 28(2): 113-118.	2020	Portugal	1, 2	53	53	8
Ong SG, Ding HJ, Zuhanis AH, Aida AA, Norazizah IW. Predictors and radiological characteristics of rheumatoid arthritis-associated interstitial lung disease in a multi-ethnic Malaysian cohort. *Med J Malaysia* 2022: 77(3): 292-299.	2022	Malaysia	1	732	54	8
Ooi GC, Mok MY, Tsang KW, Wong Y, Khong PL, Fung PC, Chan S, Tse HF, Wong RW, Lam WK, Lau CS. Interstitial lung disease in systemic sclerosis. *Acta Radiol* 2003: 44(3): 258-264.	2003	Hong Kong	2	45	39	6

Palm O, Ueland T, Garen T, Michelsen AE, Reiseter S, Aukrust P, Aalokken TM, Molberg O. Endostatin is higher and associated with pulmonary involvement in primary Sjogren's syndrome. *ClinExpRheumatol* 2016: 34(4): 690-693.	2016	Norway	4	144	36	7
Palmer E, Kelly C, Nisar M, Arthanari S, Woodhead F, PriceForbes A, Middleton D, Dempsey O, Dawson J, Sathi N, Ahmad Y, Koduri G, Young A. Rheumatoid-arthritis-related interstitial lung disease: Association between biologic therapy and survival. In; 2014 2014: (var.pagings). 53 (SUPPL. 1) (pp i44); Oxford University Press; 2014.	2014	UK	1	376	188	8
Parida P, Sahoo A, Tripathy R, Das B. Extra-articular manifestations in rheumatoid arthritis and its association with rheumatoid factor and anti-CCP. In; 2011 2011: (var.pagings). 6 (3 SUPPL. 1) (pp S9); Elsevier (Singapore) Pte Ltd; 2011.	2011	India	1	152	12	7
Park JK, George M, Danoff SK, Qubti MA, Gelber AC, ChristopherStine L. ESR and CRP do not correlate with extent of muscle injury but their elevation is associated with pulmonary involvement in Idiopathic Inflammatory myopathy. In; 2010 2010: (var.pagings). 62 (SUPPL. 10) (pp 919); John Wiley and Sons Inc.; 2010.	2010	USA	3	48	21	8
Paulin F, Doyle TJ, Mercado JF, Fassola L, Fernandez M, Caro F, Alberti ML, Espindola MEC, Buschiazzo E. Development of a Risk Indicator Score for the Identification of Interstitial Lung Disease in Patients With Rheumatoid Arthritis. *Reumatologia Clinica* 2019(Journal Article).	2019	Argentina	1	118	52	8
Paulin F, Mercado JF, Fernandez ME, Caro FM, Alberti ML, Fassola LA. Correlation between Lung and Joint Involvement in Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Cross-Sectional Study. *RevInvestClin* 2018: 70(2): 76-81.	2018	Argentina	1	46	46	7

Peng QL, Zhang YM, Liang L, Liu X, Ye LF, Yang HB, Zhang L, Shu XM, Lu X, Wang GC. A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis. *ClinExpImmunol* 2020: 199(3): 314-325.	2020	China	3	182	124	8
Perez-Dorame R, Mejia M, Mateos-Toledo H, Rojas-Serrano J. Rheumatoid arthritis-associated interstitial lung disease: lung inflammation evaluated with high resolution computed tomography scan is correlated to rheumatoid arthritis disease activity. *Reumatologia Clinica* 2015: 11(1): 12-16.	2015	Mexico	1	34	34	8
Pernot J, Puzenat E, Magy-Bertrand N, Manzoni P, Gondouin A, Bourdin H, Simon-Rigaud M-L, Regnard J, Degano B. Detection of interstitial lung disease in systemic sclerosis through partitioning of lung transfer for carbon monoxide. *Respiration* 2012: 84(6): 461-468.	2012	France	2	35	13	8
Pinal-Fernandez I, Mecoli CA, Casal-Dominguez M, Pak K, Hosono Y, Huapaya J, Huang W, Albayda J, Tiniakou E, Paik JJ, Johnson C, Danoff SK, Corse AM, Christopher-Stine L, Mammen AL. More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies. *Neurology* 2019: 93(19): e1768-e1777.	2019	USA	3	533	91	7
Ponte CB, Morais F, CampanilhoMarques R, Resende C, Pereira Da Silva J. High-resolution computed tomographic findings in patients with systemic sclerosis and their clinical correlations. In; 2013 2013: (var.pagings). 72 (SUPPL. 3) (no pagination); BMJ Publishing Group; 2013.	2013	Portugal	2	45	29	7
Poormoghim H, Andalib E, Jalali A, Ghaderi A, Ghorbannia A, Mojtabavi N. Survival and causes of death in systemic sclerosis patients: a single center registry report from Iran. *RheumatolInt* 2016: 36(7): 925-934.	2016	Iran	2	220	134	8

Proudman S. What have registries around the world taught us about systemic sclerosis? In; 2018 2018: 20th Asia Pacific League of Associations for Rheumatology Congress, APLAR 2018. Taiwan (Republic of China). 21 (Supplement 1) (pp 17-18); Blackwell Publishing; 2018.	2018	Australia	2	17838	4639	8
Qaradakhy TA, Ali KM, Karim OH. Prevalence of interstitial lung disease among patients with systemic sclerosis in Iraqi Kurdistan. In; 2012 2012: (var.pagings). 14 (SUPPL. 1) (no pagination); BioMed Central Ltd.; 2012.	2012	Iraqi Kurdistan	2	30	16	8
Qian J, He C, Peng L, Xu D, Fei Y, Zhang W, Zhao Y, Dong Y, Li Y, Zhang X, Chen H, Yang Y, Chen Z, Liu S, Wang L, Zhang F. Ten-year survival analysis of patients with primary Sjogren's syndrome in China: a national prospective cohort study. *Ther Adv Musculoskelet Dis* 2021: 13((Qian, He, Li, Peng, Yang, Xu, Fei, Zhang, Zhao, Dong, Zhang, Chen, Yang, Chen, Liu, Wang, Zhang) Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China).	2021	China	4	834	71	7
Reiseter S, Ungprasert P, Gunnarsson R, Molberg O, Lund MB, Aalokken TM, Szodoray P, Bodolay E. The development and validation of interstitial lung disease prediction models in three international mixed connective tissue disease cohorts: the Norwegian MCTD cohort, the Hungarian MCTD cohort and the MCTD cohort from Minnesota, US. In; 2018 2018: Annual European Congress of Rheumatology, EULAR 2018. Netherlands. 77 (Supplement 2) (pp 1188); BMJ Publishing Group; 2018.	2018	Norway	5	365	182	7

Richman NC, Yazdany J, Graf J, Chernitskiy V, Imboden JB. Extraarticular manifestations of rheumatoid arthritis in a multiethnic cohort of predominantly Hispanic and Asian patients. *Medicine (Baltimore)* 2013: 92(2): 92-97.	2013	USA	1	274	10	7
Rimar D, Rosner I, Slobodin G, Rozenbaum M, Halasz K, Haj T, Jiries N, Kaly L, Boulman N, Daood R, Vadas Z. Semaphorin 3A as a possible immunoregulator in systemic sclerosis. In; 2014 2014: (var.pagings). 32 (2 SUPPL. 81) (pp S66); Clinical and Experimental Rheumatology S.A.S.; 2014.	2014	Israel	2	27	10	8
Rocha-Munoz AD, Ponce-Guarneros M, Gamez-Nava JI, Olivas-Flores EM, Mejia M, Juarez-Contreras P, Martinez-Garcia EA, Corona-Sanchez EG, Rodriguez-Hernandez TM, Vazquez-del Mercado M, Salazar-Paramo M, Nava-Zavala AH, Cardona-Munoz EG, Celis A, Gonzalez-Lopez L. Anti-Cyclic Citrullinated Peptide Antibodies and Severity of Interstitial Lung Disease in Women with Rheumatoid Arthritis. *Jimmunolres* 2015: 2015(Journal Article): 151626.	2015	Mexico	1	600	39	8
RodriguezGarcia SC, CastellanosMoreira RA, HernandezMiguel MV, Ramirez J, Cuervo A, Canete J, SanmartiSala R. Clinical features and evolution of pulmonary function in a single-center cohort of patients with rheumatoid arthritis related interstitial lung disease. In; 2017 2017: Annual European Congress of Rheumatology, EULAR 2017. Spain. 76 (Supplement 2) (pp 817); BMJ Publishing Group; 2017.	2017	Spain	1	21	21	7
Salaffi F, Carotti M, Di Carlo M, Tardella M, Giovagnoni A. High-resolution computed tomography of the lung in patients with rheumatoid arthritis: Prevalence of interstitial lung disease involvement and determinants of abnormalities. *Medicine (Baltimore)* 2019: 98(38): e17088.	2019	Italy	1	151	29	8

Salaffi F, Di Carlo M, Carotti M, Fraticelli P, Gabrielli A, Giovagnoni A. Relationship between interstitial lung disease and oesophageal dilatation on chest high-resolution computed tomography in patients with systemic sclerosis: a cross-sectional study. *RadiolMed(Torino)* 2018: 123(9): 655-663.	2018	Italy	2	126	86	8
Sanchez Cano D, Callejas Rubio JL, Rios Fernandez R, Ortego Centeno N, Fonollosa V, Tolosa C, Rodriguez Carballeira M, Simeon CP. The spanish scleroderma study group: Focusing on interstitial lung disease. In; 2015 2015: (var.pagings). 74 (SUPPL. 2) (pp 823); BMJ Publishing Group; 2015.	2015	Spain	2	1374	595	7
Sargin G, Kose R, Senturk T. Tumor-associated antigens in rheumatoid arthritis interstitial lung disease or malignancy? *Archives of Rheumatology* 2018: 33(4): 431-437.	2018	Turkey	1	83	43	7
Sari A, Guven D, Armagan B, Erden A, Kalyoncu U, Karadag O, Apras Bilgen S, Ertenli I, Kiraz S, Akdogan A. Rituximab Experience in Patients With Long-standing Systemic Sclerosis-Associated Interstitial Lung Disease: A Series of 14 Patients. *Jclinrheumatol* 2017: 23(8): 411-415.	2017	Turkey	2	197	117	8
Savarino E, Bazzica M, Zentilin P, Pohl D, Parodi A, Cittadini G, Negrini S, Indiveri F, Tutuian R, Savarino V, Ghio M. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. *AmJRespirCritCare Med* 2009: 179(5): 408-413.	2009	Italy	2	40	18	8
Schnabel A, Reuter M, Biederer J, Richter C, Gross WL. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. *SeminArthritis Rheum* 2003: 32(5): 273-284.	2003	Germany	3	63	20	8
Sebastian A, MisterskaSkora M, Silicki J, Sebastian M, Wiland P. Chest HRCT findings in patients with primary Sjogren's syndrome. *Advances in Clinical and Experimental Medicine* 2017: 26(7): 1101-1106.	2017	Poland	4	68	13	8

Sebastiani M, Manfredi A, Tonelli R, Spagnolo P, Campomori F, Vacchi C, Cocconcelli E, Cerri S, Colaci M, Luppi F, Della Casa G, Sverzellati N, Torricelli P, Richeldi L, Ferri C. Rheumatoid arthritis related interstitial lung disease. Radiological patterns and correlations with clinical, serological and demographic features of disease. In; 2014 2014: (var.pagings). 73 (SUPPL. 2) (no pagination); BMJ Publishing Group; 2014.	2014	Italy	1	99	32	5
Sharma L, Raval D, Bindro M, Ekbote G, Negalur N, Tanna D, Kazi W, Rao D, Bajaj R, Gupta R. Prevalence of ILD in lupus and its serological and systemic association: A cross sectional study at a tertiary care centre in India. In; 2018 2018: Annual Conference of Indian Rheumatology Association, IRACON 2018. India. 13 (6 Supplement 1) (pp S225); Wolters Kluwer Medknow Publications; 2018.	2018	India	6	289	23	7
Siddiqui S, Coath F, Bharadwaj A, Borg F, Koduri G. Monitoring of interstitial lung disease in rheumatoid patients in routine clinical practice and therapies. In; 2018 2018: 2018 Annual Conference of the British Society for Rheumatology. United Kingdom. 57 (Supplement 3) (pp iii147); Oxford University Press; 2018.	2018	UK	1	22	22	7
Sogkas G, Hirsch S, Olsson KM, Hinrichs JB, Thiele T, Seeliger T, Skripuletz T, Schmidt RE, Witte T, Jablonka A, Ernst D. Lung Involvement in Primary Sjogren's Syndrome-An Under-Diagnosed Entity. *Frontiers in medicine* 2020: 7(101648047): 332.	2020	Germany	4	268	31	9
Sousa SI, Duarte A, Cordeiro I, Teixeira L, Canas Da Silva J, Cordeiro A, Santos MJ. Interstitial lung disease in scleroderma portuguese patients. In; 2016 2016: Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR 2016. United Kingdom. 75 (Supplement 2) (pp 1122); BMJ Publishing Group; 2016.	2016	Portugal	2	103	34	6
Steelandt A, Benmostefa N, Avouac J, Mouthon L, Allanore Y. Ethnic influence on the phenotype of French patients with systemic sclerosis. *Joint Bone Spine* 2021: 88(2): 105081.	2021	France	2	425	199	8

Tanaka A, Tsukamoto H, Mitoma H, Kiyohara C, Ueda N, Ayano M, Ohta S-i, Kimoto Y, Akahoshi M, Arinobu Y, Niiro H, Tada Y, Horiuchi T, Akashi K. Serum progranulin levels are elevated in dermatomyositis patients with acute interstitial lung disease, predicting prognosis. *Arthritis Research & Therapy* 2015: 17(Journal Article): 27.	2015	Japan	3	78	41	8
Tanaka N, Kim JS, Newell JD, Brown KK, Cool CD, Meehan R, Emoto T, Matsumoto T, Lynch DA. Rheumatoid arthritis-related lung diseases: CT findings. *Radiology* 2004: 232(1): 81-91.	2004	Japan, USA	1	63	63	8
Tanaka N, Kunihiro Y, Kubo M, Kawano R, Oishi K, Ueda K, Gondo T. HRCT findings of collagen vascular disease-related interstitial pneumonia (CVD-IP): a comparative study among individual underlying diseases. *ClinRadiol* 2018: 73(9): 833.e831-833.e810.	2018	Japan	1, 2, 3, 4, 5, 6	187	187	7
Taouli B, Brauner MW, Mourey I, Lemouchi D, Grenier PA. Thin-section chest CT findings of primary Sjogren's syndrome: Correlation with pulmonary function. *EurRadiol* 2002: 12(6): 1504-1511.	2002	France	4	35	12	8
ter Borg EJ, Kelder JC. Development of new extra-glandular manifestations or associated auto-immune diseases after establishing the diagnosis of primary Sjogren's syndrome: A long-term study of the Antonius Nieuwegein Sjogren (ANS) cohort. *RheumatolInt* 2017: 37(7): 1153-1158.	2017	Netherlands	4	140	17	7
Tezcan D, Sivrikaya A, Ergun D, Ozer H, Eryavuz Onmaz D, Korez MK, Akdag T, Gulcemal S, Limon M, Yilmaz S. Evaluation of serum interleukin-6 (IL-6), IL-13, and IL-17 levels and computed tomography finding in interstitial lung disease associated with connective tissue disease patients. *Clinical Rheumatology* 2021: 40(11): 4713-4724.	2021	Turkey	1, 2, 4	80	80	8

Tezcan D, Turan C, Yilmaz S, Sivrikaya A, Gulcemal S, Limon M, Ecer B. What do simple hematological parameters tell us in patients with systemic sclerosis? *Acta dermatovenerolog Alp Pannon Adriat* 2020: 29(3): 101-107.	2020	Turkey	2	129	63	7
Tiev KP, Hua-Huy T, Kettaneh A, Allanore Y, Le-Dong N-N, Duong-Quy S, Cabane J, Dinh-Xuan AT. Alveolar concentration of nitric oxide predicts pulmonary function deterioration in scleroderma. *Thorax* 2012: 67(2): 157-163.	2012	France	2	105	51	8
Tomita M, Kadono T, Yazawa N, Kawashima T, Tamaki Z, Ashida R, Ohmatsu H, Asano Y, Sugaya M, Kubo M, Ihn H, Tamaki K, Sato S. Serum levels of soluble CD21 in patients with systemic sclerosis. *RheumatolInt* 2012: 32(2): 317-321.	2012	Japan	2	53	24	6
Tomiyama F, Watanabe R, Ishii T, Kamogawa Y, Fujita Y, Shirota Y, Sugimura K, Fujii H, Harigae H. High Prevalence of Acute Exacerbation of Interstitial Lung Disease in Japanese Patients with Systemic Sclerosis. *Tohoku JExpMed* 2016: 239(4): 297-305.	2016	Japan	2	139	66	8
Trombetta AC, Smith V, Gotelli E, Ghio M, Paolino S, Pizzorni C, Vanhaecke A, Ruaro B, Patane M, Sulli A, Cutolo M. Vitamin d deficiency correlates with advanced organ involvement in european systemic sclerosis patients. In; 2018 2018: 5th Systemic Sclerosis World Congress. France. 3 (Supplement 1) (pp 224); SAGE Publications Inc.; 2018.	2018	Italy, Belgium	2	154	71	8
Tufvesson E, Bozovic G, Hesselstrand R, Bjermer L, Scheja A, Wuttge DM. Increased cysteinyl-leukotrienes and 8-isoprostane in exhaled breath condensate from systemic sclerosis patients. *Rheumatology* 2010: 49(12): 2322-2326.	2010	Sweden	2	22	12	6

Uh ST, Lee BY, Koo SM, Kim YK, Kim KU, Kim DJ. Change of primary Sjoren's syndrome-associated interstitial lung disease in computerized tomogram of chest during two years. In; 2018 2018: European Respiratory Society International Congress, ERS 2018. France. 52 (Supplement 62) (no pagination); European Respiratory Society; 2018.	2018	Korea	4	22	22	8
Ungprasert P, Wilton KM, Ernste FC, Kalra S, Crowson CS, Rajagopalan S, Bartholmai BJ. Novel Assessment of Interstitial Lung Disease Using the "Computer-Aided Lung Informatics for Pathology Evaluation and Rating" (CALIPER) Software System in Idiopathic Inflammatory Myopathies. *Lung* 2017: 195(5): 545-552.	2017	USA	3	110	110	7
van Bon L, Affandi AJ, Broen J, Christmann RB, Marijnissen RJ, Stawski L, Farina GA, Stifano G, Mathes AL, Cossu M, York M, Collins C, Wenink M, Huijbens R, Hesselstrand R, Saxne T, DiMarzio M, Wuttge D, Agarwal SK, Reveille JD, Assassi S, Mayes M, Deng Y, Drenth JPH, de Graaf J, den Heijer M, Kallenberg CGM, Bijl M, Loof A, van den Berg WB, Joosten LAB, Smith V, de Keyser F, Scorza R, Lunardi C, van Riel PLCM, Vonk M, van Heerde W, Meller S, Homey B, Beretta L, Roest M, Trojanowska M, Lafyatis R, Radstake TRDJ. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. *NEnglJMed* 2014: 370(5): 433-443.	2014	USA	2	779	272	7
Vandecasteele E, Melsens K, Vanhaecke A, Blockmans D, Bonroy C, Carton C, Deschepper E, De Keyser F, Houssiau F, Piette Y, Vanthuyne M, Verbeke K, Westhovens R, Wuyts WA, De Langhe E, Brusselle G, Smith V. Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders: A retrospective cohort study. *Semin Arthritis Rheum* 2021: 51(5): 969-976.	2021	Belgium	2	722	282	7

Vojinovic T, Cavazzana I, Ceruti P, Fredi M, Modina D, Berlendis M, Franceschini F. Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis. *Clin Rev Allergy Immunol* 2021: 60(1): 87-94.	2020	Italy	3	138	45	8
Voortman M, Ter Borg E, Kruize AA, Radstake TR, Zanen P, De Jong PA, Van Den Heuvel D, Grutters JC. Interstitial lung disease in patients with primary Sjogren's syndrome: Correlation of radiology, pathology, and clinical phenotype. In; 2017 2017: American Thoracic Society International Conference, ATS 2017. United States. 195 (no pagination); American Thoracic Society; 2017.	2017	Netherlands	4	39	38	6
Wang J, Wang X, Qi X, Sun Z, Zhang T, Cui Y, Shu Q. The Efficacy and Safety of Pirfenidone Combined With Immunosuppressant Therapy in Connective Tissue Disease-Associated Interstitial Lung Disease: A 24-Week Prospective Controlled Cohort Study. *Frontiers in medicine* 2022: 9(101648047): 871861.	2022	China	1, 2, 3	98	98	6
Wang J-X, Du C-G. A retrospective study of clinical characteristics of interstitial lung disease associated with rheumatoid arthritis in Chinese patients. *MedSciMonit* 2015: 21(Journal Article): 708-715.	2015	China	1	544	83	8
Wang N, Zhang Q, Jing X, Guo J, Huang H, Xu Z. The Association Between MUC5B Mutations and Clinical Outcome in Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Retrospective Exploratory Study in China. *MedSciMonit* 2020: 26(Journal Article): e920137.	2020	China	1	96	45	8
Wang T, Zheng X-J, Liang B-M, Liang Z-A. Clinical features of rheumatoid arthritis-associated interstitial lung disease. *Scientific Reports* 2015: 5(Journal Article): 14897.	2016	China	1	111	28	8

Wang Y, Chen S, Lin J, Xie X, Hu S, Lin Q, Zheng K, Du G, Huang X, Zhang G, Gargani L, Matucci-Cerinic M, Furst DE. Lung ultrasound B-lines and serum KL-6 correlate with the severity of idiopathic inflammatory myositis-associated interstitial lung disease. *Rheumatology* 2019(Journal Article).	2019	China	3	38	38	8
Wangkaew S, Euathrongchit J, Wattanawittawas P, Kasitanon N, Louthrenoo W. Incidence and predictors of interstitial lung disease (ILD) in Thai patients with early systemic sclerosis: Inception cohort study. *Modern Rheumatology* 2016: 26(4): 588-593.	2016	Thailand	2	113	81	7
Watanabe E, Gono T, Kuwana M, Terai C. Predictive factors for sustained remission with stratification by myositis-specific autoantibodies in adult polymyositis/dermatomyositis. *Rheumatology (United Kingdom)* 2020: 59(3): 586-593.	2020	Japan	3	168	88	8
Woo JH, Kim YJ, Kim JJ, Choi CB, Sung YK, Kim TH, Jun JB, Bae SC, Yoo DH. Mortality factors in idiopathic inflammatory myopathy: Focusing on malignancy and interstitial lung disease. *Modern Rheumatology* 2013: 23(3): 503-508.	2013	Korea	3	162	83	8
Wu X, Xu L, Cheng Q, Nie L, Zhang S, Du Y, Xue J. Increased serum soluble programmed death ligand 1(sPD-L1) is associated with the presence of interstitial lung disease in rheumatoid arthritis: A monocentric cross-sectional study. *Respiratory medicine* 2020: 166(Journal Article): 105948.	2020	China	1	87	58	6
Wuttge DM, Andreasson A, Tufvesson E, Johansson ACM, Scheja A, Hellmark T, Hesselstrand R, Truedsson L. CD81 and CD48 show different expression on blood eosinophils in systemic sclerosis: new markers for disease and pulmonary inflammation? *Scandinavian journal of rheumatology* 2016: 45(2): 107-113.	2016	Sweden	2	32	14	7

Yalcinkaya Y, Cinar S, Artim-Esen B, Kamali S, Ocal L, Deniz G, Inanc M. The relationship between vascular biomarkers and disease characteristics in systemic sclerosis: elevated MCP-1 is predominantly associated with fibrotic manifestations. *ClinExpRheumatol* 2016: 34(Suppl 100(5): 110-114.	2016	Turkey	2	72	18	8
Yamakawa H, Hagiwara E, Kitamura H, Yamanaka Y, Ikeda S, Sekine A, Baba T, Okudela K, Iwasawa T, Takemura T, Kuwano K, Ogura T. Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease. *Jthoracdis* 2017: 9(2): 362-371.	2017	Japan	2, 5	40	40	8
Yanaba K, Yoshizaki A, Muroi E, Ogawa F, Shimizu K, Sato S. Increased circulating soluble vascular adhesion protein-1 levels in systemic sclerosis: association with lower frequency and severity of interstitial lung disease. *International Journal of Rheumatic Diseases* 2013: 16(4): 442-447.	2013	Japan	2	71	36	6
Yang JA, Lee JS, Park JK, Lee EB, Song YW, Lee EY. Clinical characteristics associated with occurrence and poor prognosis of interstitial lung disease in rheumatoid arthritis. *Korean JInternMed* 2019: 34(2): 434-441.	2019	Korea	1	308	77	7
Yang Y, Yin G, Hao J, Xie Q, Liu Y. Serum Interleukin-18 Level is Associated With Disease Activity and Interstitial Lung Disease in Patients With Dermatomyositis. *Archives of Rheumatology* 2017: 32(3): 181-188.	2017	China	3	49	24	6
Yathish GC, Samant R, Mahashur A, Parikh T, Sagdeo P, Kakade G. Predictors of ILD and its progression in a cohort of Scleroderma patients from western India: A prospective observational cohort study. In; 2016 2016: 32nd Annual National Conference of the Indian Rheumatology Association, IRACON 2016. India. 11 (5 Supplement) (pp S71); Medknow Publications; 2016.	2016	India	2	68	53	6

Yayla ME, Balci G, Torgutalp M, Eroglu DS, Dincer ABK, Guloksuz EGA, Sezer S, Yuksel ML, Ates A, Turgay TM, Kinikli G. Interstitial Lung Disease in Systemic Sclerosis: A Single-center Retrospective Analysis. *Curr Rheumatol Rev* 2022: 18(2): 150-156.	2021	Turkey	2	226	100	8
Yazisiz V, Gocer M, Erbasan F, Ucar I, Aslan B, Oygen S, Gokalp Gok E, Terzioglu ME. Survival analysis of patients with Sjogren's syndrome in Turkey: a tertiary hospital-based study. *Clinical rheumatology* 2020: 39(1): 233-241.	2020	Turkey	4	372	47	8
Yew J, Eow LH, Liau SM, Shantene S, Chua SH, Ng KH, Asmah M, Nadiah MN, Gun SC. Clinical audit of prevalence of pulmonary manifestations among patients with rheumatoid arthritis in Hospital Tuanku Jaafar (HTJ), Seremban, Malaysia. *International Journal of Rheumatic Diseases* 2021: 24(SUPPL 2): 225-226.	2021	Malaysia	1	403	75	6
Yiu KH, Ninaber MK, Kroft LJ, Schouffoer AA, Stolk J, Scherer HU, Meijs J, De VriesBouwstra J, Tse HF, Delgado V, Bax JJ, Huizinga TWJ, Marsan NA. Impact of pulmonary fibrosis and elevated pulmonary pressures on right ventricular function in patients with systemic sclerosis. *Rheumatology (United Kingdom)* 2016: 55(3): 504-512.	2016	Netherlands	2	102	51	8
Yoshida N, Okamoto M, Kaieda S, Fujimoto K, Ebata T, Tajiri M, Nakamura M, Tominaga M, Wakasugi D, Kawayama T, Kuwana M, Mimori T, Ida H, Hoshino T. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease. *RespirInvestig* 2017: 55(1): 24-32.	2017	Japan	3	22	22	8
Young A, Vummidi D, Visovatti S, Homer K, Wilhalme H, White ES, Flaherty K, McLaughlin V, Khanna D. Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis. *Arthritis rheumatol* 2019: 71(8): 1339-1349.	2019	USA	2	93	93	8

Yu M, Guo Y, Zhang P, Xue J, Yang J, Cai Q, You X, Ma J, Yang D, Jia Y, Wang Y, Li F, Chi S, Cao M, Chen J, Liu X. Increased circulating Wnt5a protein in patients with rheumatoid arthritis-associated interstitial pneumonia (RA-ILD). *Immunobiology* 2019: 224(4): 551-559.	2019	China	1	40	40	8
Yuan L, Yao L, Zhao L, Xia L, Shen H, Lu J. Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis. *ClinExpRheumatol* 2013: 31(3): 428-432.	2013	China	3	70	35	6
Yunt ZX, Chung JH, Hobbs S, Fernandez-Perez ER, Olson AL, Huie TJ, Keith RC, Janssen WJ, Goldstein BL, Lynch DA, Brown KK, Swigris JJ, Solomon JJ. High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: Relationship to survival. *Respiratory medicine* 2017: 126(Journal Article): 100-104.	2017	USA	1	158	158	8
Yura H, Sakamoto N, Satoh M, Ishimoto H, Hanaka T, Ito C, Hasegawa T, Tanaka S, Miyamura T, Nakashima S, Hara A, Kakugawa T, Oda K, Kido T, Obase Y, Ishimatsu Y, Yatera K, Kawakami A, Mukae H. Clinical characteristics of patients with anti-aminoacyl-tRNA synthetase antibody positive idiopathic interstitial pneumonia. *Respiratory medicine* 2017: 132(Journal Article): 189-194.	2017	Japan	3	20	20	8
Zamarron-de Lucas E, Gomez Carrera L, Bonilla G, Petit D, Mangas A, Alvarez-Sala R. Antisynthetase syndrome: Analysis of 11 cases. *MedClin(Barc)* 2017: 148(4): 166-169.	2017	Spain	3	11	11	6
Zamora AC, Hoskote SS, Abascal-Bolado B, White D, Cox CW, Ryu JH, Moua T. Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome. *Respiratory medicine* 2016: 118(Journal Article): 39-45.	2016	USA	3	103	103	8

Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. Patterns of interstitial lung disease and mortality in rheumatoid arthritis. *Rheumatology* 2017: 56(3): 344-350.	2017	USA	1	181	181	8
Zanatta E, Guarnieri G, Pigatto E, Rizzo M, Campana C, Riato L, Maestrelli P, Cozzi F. Nitric oxide diffusion in patients with SSc. In; 2012 2012: (var.pagings). 51 (SUPPL. 2) (pp ii104); Oxford University Press; 2012.	2012	Italy	2	37	12	8
Zanatta E, Martini A, Scarpieri E, Biasiolo A, Ortolan A, Benvenuti F, Cozzi F, Pontisso P, Doria A. Squamous cell carcinoma antigen-IgM (SCCA-IgM) is associated with interstitial lung disease in systemic sclerosis. *Joint, Bone, Spine: Revue du Rhumatisme* 2020(Journal Article).	2020	Italy	2	97	41	8
Zhang G, Zhang X, Liu Q, Zhao Z, Lin H, Wu C. Correlation between imaging features of high-resolution computed tomography and histopathology of connective tissue diseasesassociated interstitial lung disease in Chinese Population. In; 2016 2016: 18th Asia Pacific League of Associations for Rheumatology Congress, APLAR. China. 19 (Supplement 2) (pp 94); Blackwell Publishing; 2016.	2016	China	1, 2, 3, 4, 5, 6	2320	325	8
Zhang R, Sun T, Song L, Zuo D, Xiao W. Increased levels of serum galectin-3 in patients with primary Sjogren's syndrome: associated with interstitial lung disease. *Cytokine* 2014: 69(2): 289-293.	2014	China	4	87	56	7
Zhang S, Shen H, Shu X, Peng Q, Wang G. Abnormally increased low-density granulocytes in peripheral blood mononuclear cells are associated with interstitial lung disease in dermatomyositis. *Modern Rheumatology* 2017: 27(1): 122-129.	2017	China	3	48	28	7
Zhang T, Yuan F, Xu L, Sun W, Liu L, Xue J. Characteristics of patients with primary Sjogren's syndrome associated interstitial lung disease and relevant features of disease progression. *Clinical rheumatology* 2020(Journal Article).	2020	China	4	170	85	8

Zhang T, Zhang J, Liu X, Zhang L, Zhao D, Wu X, Xu H. A clinical analysis of prognostic factors for dermatomyositis-associated interstitial lung disease. *International Journal of Clinical and Experimental Medicine* 2018: 11(6) (pp 5903-5911): Arte-Number: JEM0066897. ate of Pubaton: 0066830 Jun 0062018.	2018	China	3	103	103	8
Zhang Y, Li H, Wu N, Dong X, Zheng Y. Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease. *Clinical rheumatology* 2017: 36(4): 817-823.	2017	China	1	550	237	7
Zhao J, Liu Z, Wang Q, Xu D, Li M, Zeng X. The risk factors and prognosis of primary Sjogren's syndrome-associated interstitial lung disease: A multi-centered cohort study. In; 2019 2019: 21st Asia Pacific League of Associations for Rheumatology Congress, APLAR 2019. Australia. 22 (Supplement 3) (pp 224-225); Blackwell Publishing; 2019.	2019	China	4	1501	258	6
Zhao L, Yao L, Yuan L, Xia L, Shen H, Lu J. Potential contribution of interleukin-33 to the development of interstitial lung disease in patients with primary Sjogren's Syndrome. *Cytokine* 2013: 64(1): 22-24.	2013	China	4	110	54	6
Zhou M, Jiang L, Nie L, Chen T, Zhang T, Sun W, Sutikno J, Du Y, Xue J. Myopathy is a Risk Factor for Poor Prognosis of Patients with Systemic Sclerosis: A retrospective cohort study. *Medicine (Baltimore)* 2020: 99(33): e21734.	2020	China	2	204	129	8
Zoto A, Hafizi H, Backa T, Petrela E, Zaimi M, Harxhi A, Osmenaj R, Ylli Z. Pulmonary involvement in scleroderma. In; 2013 2013: (var.pagings). 16 (SUPPL. 1) (pp 96); Blackwell Publishing; 2013.	2013	Albania	2	58	42	7
Zuo Y, Ye L, Liu M, Li S, Liu W, Chen F, Lu X, Gordon P, Wang G, Shu X. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis. *Rheumatology* 2020(Journal Article).	2020	China	3	165	165	8

Table S5 Pooled prevalence of ILD CT patterns, by connective tissue disease**.** Data shown are pooled percent (95% confidence interval). Heterogeneity is displayed as I^2 statistic and p value.

CTD	Total N	UIP	NSIP	OP	LIP	Other	Non UIP
RA	4897	**46 (42-50)** I^2 = 88.7% p = 0.00	**35 (31-40)** I^2 = 84.1% p = 0.00	**4 (3-6)** I^2 = 60.9% p = 0.00		**17 (12-23)** I^2 = 95.3% p = 0.00	
SSc	1263	**19 (15-24)** I^2 = 72.3% p = 0.00	**76 (70-82)** I^2 = 80.6% p = 0.00			**4 (1-7)** I^2 = 81.1% p = 0.00	
IIM	1305	**8 (4-13)** I^2 = 86.6% p = 0.00	**59 (52-67)** I^2 = 83.3% p = 0.00	**16 (9-25)** I^2 = 91.2% p = 0.00		**13 (7-21)** I^2 = 91.3% p = 0.00	
pSS	722	**28 (15-43)** I^2 = 91.3% p = 0.00	**49 (39-59)** I^2 = 81.0% p = 0.00	**3 (1-6)** I^2 = 27.6% p = 0.17	**7 (2-15)** I^2 = 78.2% p = 0.00	**5 (0-15)** I^2 = 90.2% p = 0.00	
MCTD	52	**6 (1-16)** I^2 = 0.0% p = 0.41	**70 (50-87)** I^2 = 48.2% p = 0.15			**21 (5-44)** I^2 = 63.0% p = 0.07	
SLE	93	**9 (1-20)** I^2 = 51.1% p = 0.13	**27 (12-45)** I^2 = 45.2% p = 0.14			**49 (31-67)** I^2 = 60.7% p = 0.08	
UCTD	91	**37 (20-55)** I^2 = 67.0% p = 0.048					**63 (45-80)** I^2 = 61.4% p = 0.08

Abbreviations: CT: computed tomography CTD: connective tissue disease, RA: rheumatoid arthritis, SSc: systemic sclerosis, IIM: idiopathic inflammatory myositis, ILD: interstitial lung disease, LIP: lymphocytic interstitial pneumonia, MCTD: mixed connective tissue disease, NSIP: non-specific interstitial pneumonia, OP: organizing pneumonia, Other: other and undifferentiated, pSS: primary Sjögren syndrome, SLE: systemic lupus erythematosus, UCTD: undifferentiated connective tissue disease, UIP: usual interstitial pneumonia.